<SEC-DOCUMENT>0001493152-25-012316.txt : 20250826
<SEC-HEADER>0001493152-25-012316.hdr.sgml : 20250826
<ACCEPTANCE-DATETIME>20250826073022
ACCESSION NUMBER:		0001493152-25-012316
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250825
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250826
DATE AS OF CHANGE:		20250826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Curanex Pharmaceuticals Inc
		CENTRAL INDEX KEY:			0002025942
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				830741390
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42815
		FILM NUMBER:		251252619

	BUSINESS ADDRESS:	
		STREET 1:		2 JERICHO PLAZA,
		STREET 2:		SUITE101B
		CITY:			JERICHO
		STATE:			NY
		ZIP:			11753
		BUSINESS PHONE:		718-673-6078

	MAIL ADDRESS:	
		STREET 1:		2 JERICHO PLAZA,
		STREET 2:		SUITE101B
		CITY:			JERICHO
		STATE:			NY
		ZIP:			11753
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CURX="http://curanexpharmaceuticalsinc.com/20250825">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_CURX_curanexpharmaceuticalsinc.com_20250825 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250825_20250825 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0002025942 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000004" name="dei:EntityCentralIndexKey">0002025942</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="curx-20250825.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002025942</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-25</xbrli:startDate>
        <xbrli:endDate>2025-08-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20250825__20250825_zzkMP5d5RSV8"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported):</b></span> <span id="xdx_90C_edei--DocumentPeriodEndDate_c20250825__20250825_z7CsrdvH51eh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August
25, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20250825__20250825_zWvRtUzBWoVk"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000011" name="dei:EntityRegistrantName">Curanex
Pharmaceuticals Inc</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20250825__20250825_zpaWEwewWqef"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90E_edei--EntityFileNumber_c20250825__20250825_zfAeYNKj9Nd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000013" name="dei:EntityFileNumber">333-282686</ix:nonNumeric></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250825__20250825_zo1DtR1gFZo7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000014" name="dei:EntityTaxIdentificationNumber">83-0741390</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20250825__20250825_zkLF3zC2yYk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000015" name="dei:EntityAddressAddressLine1">2
                                            Jericho Plaza</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
                                            <span id="xdx_906_edei--EntityAddressAddressLine2_c20250825__20250825_zoQNfMFoq383"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
                                            101B</ix:nonNumeric></span></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_900_edei--EntityAddressCityOrTown_c20250825__20250825_zNzlJwTpRbT3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000017" name="dei:EntityAddressCityOrTown">Jericho</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_907_edei--EntityAddressStateOrProvince_c20250825__20250825_zX97fOkbvJ1a"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000018" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric> </span></span></b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20250825__20250825_zSVdqW0i2R4g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000019" name="dei:EntityAddressPostalZipCode">11753</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_909_edei--CityAreaCode_c20250825__20250825_z3ebaau1Re45" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000020" name="dei:CityAreaCode">(718)</ix:nonNumeric></span></b></span><b><span style="text-decoration: underline">
<span id="xdx_904_edei--LocalPhoneNumber_c20250825__20250825_zFgCmFZyelL" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000021" name="dei:LocalPhoneNumber">673-6078</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">N/A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_907_edei--WrittenCommunications_c20250825__20250825_zkNcsOEMrBy9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_edei--SolicitingMaterial_c20250825__20250825_zPwm9zwQrZHh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_900_edei--PreCommencementTenderOffer_c20250825__20250825_zlM6hSlp7pye" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20250825__20250825_zeuWZDhknvAk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_edei--Security12bTitle_c20250825__20250825_zyt9kpHLUpC8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_edei--TradingSymbol_c20250825__20250825_zIpZheY5J65a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-25" id="Fact000027" name="dei:TradingSymbol">CURX</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90F_edei--SecurityExchangeName_c20250825__20250825_ztnnafdNG1f8"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250825__20250825_za6m9svPpT4k"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_900_edei--EntityExTransitionPeriod_c20250825__20250825_zP73GO9fOQkj"><ix:nonNumeric contextRef="AsOf2025-08-25" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 25, 2025, Curanex Pharmaceuticals Inc, a Nevada corporation (the &#8220;Company&#8221;), entered into an underwriting agreement
(the &#8220;Underwriting Agreement&#8221;) with Dominari Securities, LLC, as representative of the underwriters named on Schedule I therein,
pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten initial public offering (the &#8220;Offering&#8221;)
an aggregate of 3,750,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at
a public offering price of $4.00 per share, for gross Offering proceeds of $15,000,000. The Company has also granted the underwriters
a 45-day option to purchase up to 562,500 additional shares of Common Stock to cover over-allotments, if any. The Offering is expected
to close on August 27, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Common Stock were offered by the Company pursuant to a registration statement on Form S-1, as amended (File No. 333-282686),
filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;), which was declared effective by the Commission on August
12, 2025 (the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Offering, after deducting the underwriting discount, the underwriters&#8217; fees and expenses and
the Company&#8217;s estimated Offering expenses, are expected to be approximately $12,114,369.</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates using the net proceeds from the Offering
for (i) the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis; (ii) to conduct FDA-required
good laboratory practice (&#8220;GLP&#8221;) toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, (iii) to prepare
and submit an Investigational New Drug (IND) application, and (iv) for working capital and other general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations and warranties that the parties made to, and solely for the benefit of, the
other party in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between
the parties. The provisions of the Underwriting Agreement, including the representations and warranties contained therein, are not for
the benefit of any party other than the parties to such agreements and are not intended as documents for investors and the public to
obtain factual information about the current state of affairs of the parties to those documents and agreements. Rather, investors and
the public should look to other disclosures contained in the Company&#8217;s filings with the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summary of the terms of the Underwriting Agreement is subject to, and qualified in its entirety by reference to, a copy of
the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2025, we released the press release furnished herewith as Exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
    Pharmaceuticals Inc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 26, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jun Liu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jun
    Liu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5Fm0rivbToiJWkSLi72hTGWwnJTO+luQujS1iuJDXPYlSPbWkhamQ4TjLM9hj3VTaI+RYIqM9ozjS1ToByTlejPOsrW/bH5iSMCjMuB+dZN4678ZhkUA4GcQjkRTJcAq7jQq++5RsaQq03ugKtC1gx9SwQa/51V3Y6ydZql/tpwOyM2QTiPpht35DHEYxbOmuH8RXB1mWqqDXRqCWTLdGXPOnR/slYV5hLe9cR/8VfADUUkpr -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOMINARI
SECURITIES LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">725
5th Ave 23rd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
Pharmaceuticals Inc, a corporation incorporated under the law of the State of Nevada (the &ldquo;<B><I>Company</I></B>&rdquo;), agrees,
subject to the terms and conditions in this agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;), to issue and sell to Dominari Securities
LLC acting as the representative (the &ldquo;<B><I>Representative</I></B>&rdquo;) of the underwriters named on <U>Schedule I</U> hereto.
(each an &ldquo;<B><I>Underwriter</I></B>&rdquo; and together, the &ldquo;<B><I>Underwriters</I></B>&rdquo;) an aggregate of 3,750,000
shares (the &ldquo;<B><I>Closing Shares</I></B>&rdquo;) of its common stock, par value $0.0001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;).
No Closing Shares will be certificated. At the option of the Underwriters, the Company agrees, subject to the terms and conditions herein,
to issue and sell additional Option Shares (as defined in Section 3(b) hereof). The Closing Shares and the Option Shares are herein referred
to collectively as the &ldquo;<B><I>Securities</I></B>.&rdquo; The number of Closing Shares and Option Shares to be purchased by each
Underwriter is set forth opposite its name in Schedule I hereto. Each of the Underwriters has agreed to act as underwriters in connection
with the offering and sale of the Securities. The offering and sale of the Securities is herein referred to as the &ldquo;<B><I>Offering</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><U>Representations and Warranties of the Company</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby represents and warrants to, and agrees with, the Underwriters as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company has prepared and filed the Registration Statement with the Commission under the Securities Act. The Commission has declared
the Registration Statement effective under the Securities Act and the Company has not as of the date of this Agreement filed a post-effective
amendment to the Registration Statement. The Commission has not issued any order suspending the effectiveness of the Registration Statement
or any order preventing or suspending the use of the Registration Statement, the Final Prospectus, any Preliminary Prospectus or any
Issuer Free Writing Prospectus, and no proceedings for such purpose or pursuant to Section 8A of the Securities Act have been initiated,
are pending before or, to the Company&rsquo;s knowledge, threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Registration Statement, at the time it became effective, did not contain, and any post-effective amendment thereto, as of the effective
date of such amendment, will not contain, any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading; provided, that the Company makes no representation or warranty with
respect to any statements or omissions made in reliance upon and in conformity with information relating to the Underwriters furnished
to the Company in writing by the Underwriters for use in the Registration Statement (including any post-effective amendment thereto),
the Pricing Disclosure Package, the Final Prospectus (including any amendments or supplements thereto), any Preliminary Prospectus, any
Issuer Free Writing Prospectus or any Testing-the-Waters Communication, it being understood and agreed that the only such information
furnished by the Underwriters consists of the information described in Section 8(b) hereof (collectively, the &ldquo;<B><I>Underwriter
Information</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective and at the date hereof,
complied and will comply in all material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Pricing Disclosure Package</U>. The Pricing Disclosure Package, as of the Applicable Time, did not, and as of the Closing Date (as
defined below) and as of any Additional Closing Date (as defined below), as the case may be, will not, contain any untrue statement of
a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements
or omissions made in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Final Prospectus</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each of the Final Prospectus and any amendments or supplements thereto, as of its date, as of the time it is filed with the Commission
pursuant to Rule 424(b) under the Securities Act, as of the Closing Date and as of any Additional Closing Date, as the case may be, will
not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty
with respect to any statements or omissions made in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Each of the Final Prospectus and any amendments or supplements thereto, at the time it is filed with the Commission pursuant to Rule
424(b) under the Securities Act, as of the Closing Date and as of any Additional Closing Date, as the case may be, will comply in all
material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Preliminary Prospectuses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each Preliminary Prospectus, as of the time it was filed with the Commission pursuant to Rule 424(a) under the Securities Act, if any,
did not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Each Preliminary Prospectus, at the time it was filed with the Commission pursuant to Rule 424(a) under the Securities Act, if any, complied
in all material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Issuer Free Writing Prospectuses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each Issuer Free Writing Prospectus, when considered together with the Preliminary Prospectus accompanying, or delivered prior to the
delivery of, such Issuer Free Writing Prospectus, did not, as of the date of such Issuer Free Writing Prospectus, and will not, as of
the Closing Date and as of any Additional Closing Date, as the case may be, conflict in any material respect with the information contained
in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any
statements or omissions made in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Each Issuer Free Writing Prospectus, at the time of filing with the Commission, complied or will comply in all material respects with
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company has filed, or will file, with the Commission, within the time period specified in Rule 433(d) under the Securities Act, any
Free Writing Prospectus it is required to file pursuant to Rule 433(d) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Except for the Issuer Free Writing Prospectuses, if any, set forth in Schedule II hereto and electronic road shows, if any, each furnished
to the Underwriters before first use, the Company has not used, authorized the use of, referred to or participated in the planning for
use of, and will not, without the prior consent of the Underwriters, use, authorize the use of, refer to or participate in the planning
for use of, any Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Testing-the-Waters Communications</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not (x) alone engaged in any Testing-the-Waters Communication and (y) authorized anyone to engage in Testing-the-Waters Communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>No Other Disclosure Materials</U>. Other than the Registration Statement, the Pricing Disclosure Package, the Final Prospectus and
the Road Show, the Company (including its agents and representatives, other than the Underwriters, as to which no representation or warranty
is given) has not, directly or indirectly, distributed, prepared, used, authorized, approved or referred to, and will not distribute,
prepare, use, authorize, approve or refer to, any offering material in connection with the offering and sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Ineligible Issuer</U>. At the time that the Registration Statement was first filed with the Commission, the Company was not and is
not an &ldquo;ineligible issuer&rdquo; as defined in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Emerging Growth Company</U>. From the time that the Registration Statement was first filed with the Commission (or, if earlier, the
first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication)
through the date hereof, the Company has been and is an Emerging Growth Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Due Authorization</U>. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the consummation by it of the transactions contemplated hereby and thereby has been duly and validly taken<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Underwriting Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company and each, assuming the
due authorization, execution and delivery by the other parties hereto and thereto, constitutes the legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms, except as (i) the enforcement may be limited by bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of
creditors generally or by general equitable principles (whether considered in a proceeding at law or in equity) relating to enforceability
and (ii) rights to indemnification and contribution hereunder may be limited by applicable law and public policy considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>No Material Adverse Change</U>. Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the
Final Prospectus (in each case exclusive of any amendment or supplement thereto), since the date of the most recent financial statements
included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus: (i) there has been no material adverse
change, or any development that would result in a material adverse change, in or affecting the condition (financial or otherwise), earnings,
business, properties, management, financial position, stockholders&rsquo; equity, or results of operations, whether or not arising from
transactions in the ordinary course of business, of the Company and its subsidiaries, considered as a whole; (ii) there has been no change
in the share capital of the Company (other than (A) the issuance of shares of Common Stock upon the exercise or settlement (including
any &ldquo;net&rdquo; or &ldquo;cashless&rdquo; exercises or settlements) of stock options, restricted share units or warrants described
as outstanding, (B) the grant of options and awards under existing equity incentive plans, or (C) the repurchase of shares of Common
Stock by the Company, which were issued pursuant to the early exercise of stock options by option holders and are subject to repurchase
by the Company, in each case, as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus), or
material change in the short-term debt or long-term debt of the Company or any of its subsidiaries, considered as a whole, and (iii)
the Company and its subsidiaries, considered as a whole, have not incurred any material liability or obligation, indirect, direct or
contingent (whether or not in the ordinary course of business); nor entered into any transaction or agreement (whether or not in the
ordinary course of business) that is material to the Company and its subsidiaries, considered as a whole; and (iv) there has been no
dividend or distribution of any kind declared, set aside for payment, paid or made by the Company or, except for dividends paid to the
Company or other subsidiaries of the Company, any of its subsidiaries on any class of capital stock or repurchase or redemption by the
Company or any of its subsidiaries of any class of capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Organization and Good Standing of the Company and its Subsidiaries</U>. Each of the Company and its subsidiaries has been duly organized
or incorporated and is validly existing and in good standing under the law of their respective jurisdictions of organization or incorporation,
is duly qualified to do business and is in good standing in each jurisdiction in which its respective ownership or lease of property
or the conduct of its businesses requires such qualification, and has all power and authority (corporate and other) necessary to own,
lease or hold its properties and to conduct the businesses in which they are engaged as described in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus, except where the failure to be in good standing, to be so qualified or to have such
power or authority would not, individually or in the aggregate, have a material adverse effect on the condition (financial or otherwise),
earnings, business, properties, management, financial position, stockholders&rsquo; equity, or results of operations of the Company and
its subsidiaries, considered as a whole, or adversely affect the performance by the Company of its obligations under this Agreement (a
&ldquo;<B><I>Material Adverse Effect</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Capitalization</U>. The capitalization of the Company is as set forth in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus under the heading &ldquo;Capitalization&rdquo;. All of the outstanding shares of the Company have been duly
authorized and validly issued and are fully paid and non-assessable. The Securities and the Underwriters&rsquo; Securities (as defined
in Section 3(b)(vi)) have been duly authorized and, when issued and paid for as contemplated herein, will be validly issued, fully paid
and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Securities
and the Underwriters&rsquo; Securities are not and will not be subject to the preemptive rights of any holders of any security of the
Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance
and sale of the Securities and the Underwriters&rsquo; Securities has been duly and validly taken. None of the outstanding shares of
Common Stock of the Company were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase securities of the Company. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the
Final Prospectus, there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights
to acquire, or instruments convertible into or exchangeable or exercisable for, any shares of, or other equity interest in, the Company
or any of its subsidiaries. All of the outstanding shares of, or other equity interest in, each of the Company&rsquo;s subsidiaries (i)
have been duly authorized and validly issued, (ii) are fully paid and non-assessable and (iii) are owned by the Company, directly or
through the Company&rsquo;s subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, charge, claim
or restriction on voting or transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Stock Plans</U>. The Company does not have any stock plans as of the date of this Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>No Violation or Default</U>. Neither the Company nor any of its subsidiaries is: (i) in violation of its articles of incorporation,
by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any term, covenant, condition or other obligation contained in any
indenture, mortgage, deed of trust, loan agreement, contract, undertaking or other agreement or instrument to which the Company or any
of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of
the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute applicable to the Company or any of its
subsidiaries or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction
over the Company or any of its subsidiaries, or any of their respective properties or assets, except, in the case of clauses (ii) and
(iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>No Conflicts</U>. None of (i) the execution, delivery and performance of this Agreement by the Company, (ii) the issuance, sale and
delivery of the Securities, (iii) the application of the proceeds of the offering as described under &ldquo;Use of Proceeds&rdquo; in
the Registration Statement, the Pricing Disclosure Package and the Final Prospectus, or (iv) the consummation of the transactions contemplated
herein will: (x) result in any violation of the terms or provisions of the charter, by-laws or similar organizational documents of the
Company or any of its subsidiaries; (y) conflict with, result in a breach or violation of, or require the approval of stockholders or
any approval or consent of any persons under, any of the terms or provisions of, constitute a default under, result in the termination,
modification, or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right
or asset of the Company or any of its subsidiaries pursuant to, any material indenture, mortgage, deed of trust, loan agreement, note
agreement, contract, undertaking or other material agreement, obligation, condition, covenant or instrument to which the Company or any
of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of
the Company or any of its subsidiaries is subject; or (z) result in the violation of any law, statute or regulation applicable to the
Company or any of its subsidiaries or any judgment, order, rule, decree of any court, arbitrator, governmental or regulatory authority,
agency or body having jurisdiction over the Company or any of its subsidiaries or any of their respective properties or assets, which
would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>No Consents Required</U>. No consent, approval, authorization, order, filing, registration, license or qualification of or with any
court, arbitrator, or governmental or regulatory authority, agency, or body is required for (i) the execution, delivery and performance
by the Company of this Agreement; (ii) the issuance, sale and delivery of the Securities; or (iii) the consummation of the transactions
contemplated herein, except for such consents, approvals, authorizations, orders, filings, registrations or qualifications as (x) have
already been obtained or made and are still in full force and effect, (y) may be required by FINRA and The Nasdaq Stock Market LLC (&ldquo;<B><I>Nasdaq</I></B>&rdquo;),
and (z) may be required under applicable state securities laws in connection with the purchase, distribution and resale of the Securities
by the Underwriters<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Independent Accountants</U>. Kreit and Chiu CPA LLP (the &ldquo;<B><I>Auditor</I></B>&rdquo;), which expressed its opinion with respect
to the financial statements (which term as used in this Agreement includes the related notes thereto) included in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus, is an independent registered public accounting firm with respect to the Company
and its subsidiaries within the meaning of the rules and regulations of the Commission and the Public Company Accounting Oversight Board
and as required by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Financial Statements and Other Financial Data</U>. The financial statements (including the related notes thereto), together with the
supporting schedules, included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus comply in all material
respects with the applicable requirements of the Securities Act and present fairly in all material respects the financial position of
the entities to which they relate as of and at the dates indicated and the results of their operations and cash flows for the periods
specified. Such financial statements, notes and schedules have been prepared in conformity with GAAP applied on a consistent basis throughout
the periods involved, except as may be expressly stated in the notes thereto. The financial data set forth in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus under the captions &ldquo;Capitalization&rdquo; present fairly the information
set forth therein on a basis consistent with that of the audited financial statements included in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Statistical and Market-Related Data</U>. The statistical and market-related data included in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus are based on or derived from sources that the Company reasonably and in good faith believes
to be accurate and reliable in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Industry Data; Forward-Looking Statements</U><I>.</I> The statistical and market-related data included in each of the Registration
Statement, the General Disclosure Package, and the Prospectus are based on or derived from sources that the Company reasonably and in
good faith believes are reliable and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data
derived from such sources. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the
Exchange Act) contained in the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in
good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Legal Proceedings</U>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
(i) there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings
(collectively, &ldquo;<B><I>Actions</I></B>&rdquo;) pending to which the Company or any of its subsidiaries is or may be a party or to
which any property, right or asset of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate,
if determined adversely to the Company or any of its subsidiaries, would have a Material Adverse Effect; and (ii) to the knowledge of
the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Labor Disputes</U>. No labor disturbance by or dispute with the employees of the Company or any of its subsidiaries exists or, to
the knowledge of the Company, is threatened or contemplated that would, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Intellectual Property Rights</U>. (i) The Company and its subsidiaries own or have the right to use all patents, patent applications,
trademarks, service marks, trade names, and other source indicators and registrations and applications for registration thereof, domain
name registrations, copyrights and registrations and applications for registration thereof, technology and know-how, trade secrets, and
all other intellectual property and related proprietary rights (collectively, &ldquo;<B><I>Intellectual Property Rights</I></B>&rdquo;)
necessary to conduct their respective businesses in all material respects; (ii) other than as disclosed in the Prospectus, neither the
Company nor any of its subsidiaries has received any notice of infringement, misappropriation or other conflict with (and neither the
Company nor any of its subsidiaries is otherwise aware of any infringement, misappropriation or other conflict with) the Intellectual
Property Rights of any other person, except for such infringement, misappropriation or other conflict as would not have a Material Adverse
Effect; and (iii) to the knowledge of the Company, the Intellectual Property Rights of the Company and its subsidiaries are not being
infringed, misappropriated or otherwise violated by any person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Licenses and Permits</U>. (i) The Company and its subsidiaries possess such valid and current certificates, authorizations, approvals,
licenses and permits (collectively, &ldquo;<B><I>Authorizations</I></B>&rdquo;) issued by, and have made all declarations, amendments,
supplements and filings with, the appropriate state, federal or foreign regulatory agencies or bodies necessary to own, lease and operate
their respective properties and to conduct their respective businesses as set forth in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus; (ii) all such Authorizations are valid and in full force and effect and the Company and its subsidiaries
are in compliance with the terms and conditions of all such Authorizations; and (iii) neither the Company nor any of its subsidiaries
has received notice of any revocation, termination or modification of, or non-compliance with, any such Authorization or has any reason
to believe that any such Authorization will not be renewed in the ordinary course, except where, in the case of clauses (i), (ii) and
(iii), the failure to possess, make or obtain such Authorizations (by possession, declaration or filing) would not, individually or in
the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Title to Property</U>. Neither the Company nor any of its subsidiaries own any real property. The Company and its subsidiaries have
good and marketable title in fee simple to, or have valid and enforceable rights to lease or otherwise use, all items of personal property
(other than with respect to Intellectual Property Rights, which is addressed exclusively in Section 1(y)) that are material to the respective
businesses of the Company and its subsidiaries, in each case, free and clear of all liens, encumbrances, claims, and defects and imperfections
of title, except such liens, encumbrances, claims, defects and imperfections as (i) are disclosed in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus, or (ii) do not materially affect the value of such property and do not materially
interfere with the use made or proposed to be made of such property by the Company and its subsidiaries. The Company and its subsidiaries
have good and marketable title in fee simple to, or have valid and enforceable rights to lease or otherwise use, all items of real and
personal property that are material to the respective businesses of the Company and its subsidiaries, in each case, free and clear of
all liens, encumbrances, claims and defects and imperfections of title, except such liens, encumbrances, claims, defects and imperfections
as (i) are disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus, or (ii) do not materially
affect the value of such property and do not materially interfere with the use made or proposed to be made of such property by the Company
and its subsidiaries. All items of real and personal property held under lease by the Company and its subsidiaries are held under valid,
subsisting and enforceable leases, with such exceptions as do not materially interfere with the use made or proposed to be made of such
property by the Company and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Taxes</U>. The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed
through the date hereof or have timely requested extensions thereof and have paid all taxes required to be paid thereon (except as currently
being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company).
The charges, accruals and reserves in respect of any income and other tax liability in the financial statements of the Company referred
to in Section 1(t) are adequate, in accordance with GAAP principles, to meet any assessments for any taxes of the Company accruing through
the end of the last period specified in such financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Investment Company Act</U>. Neither the Company nor any of its subsidiaries is or, after giving effect to the offer and sale of the
Securities and the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus, will be required to register as an &ldquo;investment company&rdquo; (as defined
in the Investment Company Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Insurance</U>. The Company carries or is entitled to the benefits of insurance, with reputable insurers, and in such amounts and covering
such risks which the Company believes are reasonably adequate, and all such insurance is in full force and effect. The Company has no
reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain
comparable or new coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and
at a cost that would not reasonably be expected to result in a Material Adverse Effect. The Company and its subsidiaries are in compliance
with the terms of such policies in all material respects; neither the Company nor any of its subsidiaries has received notice from any
insurer or agent of such insurer that capital improvements or other expenditures (other than premiums) are required to be made in order
to continue such insurance; and neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied
for. There are no claims by the Company or any of its subsidiaries under any such policy as to which any insurer is denying liability
or defending under a reservation of rights clause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>No Stabilization or Manipulation</U>. None of the Company, its Affiliates or any person acting on its or any of their behalf (other
than the Underwriters, as to which no representation or warranty is given) has taken, directly or indirectly, any action designed to
or that has constituted or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of
any securities of the Company. The Company acknowledges that the Underwriters may engage in passive market making transactions in the
shares of Common Stock on the Nasdaq (the &ldquo;<B><I>Exchange</I></B>&rdquo;) in accordance with Regulation M under the Exchange Act
(&ldquo;<B><I>Regulation M</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Compliance with the Sarbanes-Oxley Act</U>. The Company will implement such programs and take reasonable steps to ensure the Company&rsquo;s
compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the applicable provisions of the Sarbanes-Oxley
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Accounting Controls</U>. The Company and its subsidiaries maintain a system of internal accounting controls designed to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Other than as disclosed in the Registration Statement, since the date of the most recent balance sheet included in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus, (x) the Company&rsquo;s auditors have not been advised
of (A) any new significant deficiencies or material weaknesses in the design or operation of the internal control over financial reporting
of the Company and its subsidiaries which could adversely affect the Company&rsquo;s ability to record, process, summarize, and report
financial data; or (B) any fraud, whether or not material, that involves management or other employees who have a role in the internal
control over financial reporting of the Company or its subsidiaries; and (y) there have been no significant changes in the internal control
over financial reporting of the Company or its subsidiaries or in other factors that could significantly affect, such internal control
over financial reporting, since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Disclosure Controls and Procedures</U>. The Company has developed and currently maintains disclosure controls and procedures that
will comply with Rule 13a-15 under the Exchange Act Regulations applicable to it, and such controls and procedures are effective to ensure
that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation
of the Company&rsquo;s Exchange Act filings and other public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Compliance with Environmental Laws</U>. The Company and each of its subsidiaries (i) are, and at all times prior hereto were, in compliance
with all Environmental Laws (as defined below) applicable to such entity, which compliance includes, without limitation, obtaining, maintaining
and complying with all permits and authorizations and approvals required by Environmental Laws to conduct their respective businesses;
and (ii) have not received notice or otherwise have knowledge of any actual or alleged violation of Environmental Laws, or of any actual
or potential liability for or other obligation concerning the presence, disposal or release of hazardous or toxic substances or wastes,
pollutants or contaminants, and, except as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
(x) there are no proceedings that are pending, or known to be contemplated, against the Company or any of its subsidiaries under Environmental
Laws, other than such proceedings regarding which it is reasonably believed that no monetary sanctions of $100,000 or more will be imposed;
and (y) none of the Company or any of its subsidiaries is aware of any issues regarding compliance with Environmental Laws, including
any pending or proposed Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic
substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures,
earnings or competitive position of the Company and its subsidiaries; and (z) none of the Company or any of its subsidiaries currently
anticipates material capital expenditures relating to Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, the term <B><I>&ldquo;Environmental Laws&rdquo;</I></B> means any laws, regulations, ordinances, rules, orders, judgments,
decrees, permits or other legal requirements of any governmental authority, including, without limitation, any international, foreign,
national, state, provincial, regional, or local authority, relating to pollution, the protection of human health or safety, the environment,
or natural resources, or to the use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release of hazardous
or toxic substances or wastes, pollutants or contaminants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Related Party Transactions</U>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
no relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors,
officers, stockholders, other Affiliates, customers or suppliers of the Company or any of its subsidiaries, on the other hand, that would
be required by the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>No Unlawful Contributions or Other Payments</U>. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company,
any director, officer, agent, employee, Affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries
has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity;
(ii) made any direct or indirect unlawful payment to any foreign or domestic government or regulatory official or employee; (iii) made
any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (iv) violated or is in violation of any provision
of (y) the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &ldquo;<B><I>FCPA</I></B>&rdquo;),
or (z) any non-U.S. anti-bribery or anti-corruption statute or regulation. The Company and its subsidiaries will institute and maintain
and enforce policies and procedures designed to comply with all applicable anti-bribery and anti-corruption laws, no later than the relevant
statutory and regulatory deadlines therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Compliance with Anti-Money Laundering Laws</U>. The operations of the Company are and have been conducted at all times in compliance
in all material respects with applicable financial recordkeeping and reporting requirements of the U.S. Currency and Foreign Transactions
Reporting Act of 1970, as amended, including the U.S. Money Laundering Control Act of 1986, as amended, the rules and regulations thereunder,
the rules and regulations thereunder, the U.K. Proceeds of Crime Act 2002, Terrorist Financing and Transfer of Funds (Information on
the Payer) Regulations 2017 and Sanctions and Anti-Money Laundering Act 2018 and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;); and no
action, suit or proceeding by or before any Governmental Entity involving the Company with respect to Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Compliance with Sanctions Laws</U>. Neither the Company nor, to the knowledge of the Company, any directors, officers or employees
of the Company or any agent, affiliate or other person associated with or acting on behalf of the Company is currently the subject or
the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Asset
Control (OFAC) of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European
Union, the Office of Financial Sanctions Implementation of the United Kingdom of Great Britain and Northern Ireland (OFSI) or other relevant
sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor is the Company located, organized or resident in a country
or territory that is the subject or target of Sanctions, including, without limitation, the Republic of Belarus, Crimea, the Russian
Federation, Republic of Cuba, the Islamic Republic of Iran, Democratic People&rsquo;s Republic of Korea (North Korea), the Syrian Arab
Republic, the Bolivarian Republic of Venezuela and the Republic of Yemen (each, a &ldquo;<B><I>Sanctioned Country</I></B>&rdquo;); and
the Company will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person
that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of
or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person
participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past three years, the
Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any person that at the time
of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>No Registration Rights</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
there are no contracts, agreements or understandings between the Company or any of its subsidiaries, on the one hand, and any person,
on the other hand, granting such person any rights (except for any such rights that have been waived) to require the Company or any of
its subsidiaries to file a registration statement under the Securities Act with respect to any securities of the Company or any of its
subsidiaries owned or to be owned by such person or to require the Company or any of its subsidiaries to include such securities in any
securities to be registered pursuant to any registration statement to be filed by the Company or any of its subsidiaries under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Subsidiaries</U>. The Company does not own or control, directly or indirectly, any corporation, association or other entity, other
than the subsidiaries listed in Schedule III attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>No Restrictions on Subsidiaries</U>. No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any
dividends to the Company, from making any other distribution on such subsidiary&rsquo;s capital stock or similar ownership interest,
from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&rsquo;s
properties or assets to the Company or any other subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>No Broker&rsquo;s Fees</U>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this
Agreement) that would give rise to a valid claim against any of them or any of the Underwriters for a brokerage commission, finder&rsquo;s
fee or like payment in connection with the offering and sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Exchange Listing</U>. Subject to notice of issuance, the Closing Shares and the Option Shares have been approved for listing on the
Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Lock-Up Agreements</U>. Schedule IV hereto contains a complete and accurate list of the Company&rsquo;s directors, officers, employees
and each owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock (or securities convertible or exercisable into
such shares) (collectively, the &ldquo;<B><I>Lock-Up Parties</I></B>&rdquo;). The Company has requested that each of the Lock-Up Parties
deliver to the Underwriters an executed Lock-Up Agreement substantially in the form of Exhibit A hereto (each, a &ldquo;<B><I>Lock-Up
Agreement</I></B>&rdquo;), on or prior to the date of this Agreement. The Underwriters may, in their sole discretion, agree to waive
and release any director or officer of the Company from the restrictions of the Lock-Up Agreement to which one or more of them is party.
In such case, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit
C hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<FONT STYLE="background-color: white"><U>Clinical Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and
other studies (collectively, &ldquo;<B><I>studies</I></B>&rdquo;) that are described in, or the results of which are referred to in,
</FONT>Registration Statement, the Pricing Disclosure Package or the Prospectus <FONT STYLE="background-color: white">were and, if still
pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food
and Drug Administration of the U.S. Department of Health and Human Services (the &ldquo;<B><I>FDA</I></B>&rdquo;) or any committee thereof
or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review
Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data
derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially
inconsistent with, or otherwise call into question, the results described or referred to in the </FONT>Registration Statement, the Pricing
Disclosure Package or the Prospectus<FONT STYLE="background-color: white">; for such studies that have been or are being conducted, the
Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug
or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application
filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither
the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any
action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed
to be conducted by or on behalf of the Company or any of its subsidiaries.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
<U>Regulatory Compliance</U>. <FONT STYLE="background-color: white">Except as described in the </FONT>Registration Statement, the Pricing
Disclosure Package or the Prospectus<FONT STYLE="background-color: white">, and except as could not, individually or in the aggregate,
have or may reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries are, and at all time since inception
have been, in compliance with all applicable Health Care Laws, and have not engaged in activities which are, as applicable, cause for
false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state health care
program or federal health care program. The Company is not a party to any corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any governmental authority regarding any alleged non-compliance
with applicable Health Care Laws. In addition, none of the Company or its subsidiaries or, to the Company&rsquo;s knowledge, any of their
respective directors, officers, employees or agents is or has been debarred, suspended or excluded, or has been convicted of any crime
or, to the knowledge of the Company or its subsidiaries, engaged in any conduct that would result in a debarment, suspension or exclusion
from any federal or state government health care program or human clinical research, or, to the knowledge of the Company, is subject
to any inquiry, investigation, proceeding, or other similar action by a governmental authority that could reasonably be expected to result
in any such debarment, suspension, or exclusion.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means: the federal Food, Drug and Cosmetic Act (21 U.S.C. &sect; 301
et seq.), the federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the civil False Claims Act (31 U.S.C. &sect; 3729 et seq.),
the federal False Statements Law (42 U.S.C. &sect; 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. &sect;1320a-7a), all criminal
laws relating to health care fraud and abuse, including, but not limited, to 18 U.S.C. &sect;&sect; 286 and 287, the exclusions law (42
U.S.C. &sect; 1320a-7), the statutes, regulations and directives of Medicare (Title XVIII of the Social Security Act), Medicaid (Title
XIX of the Social Security Act) and all other government funded or sponsored healthcare programs, the Health Insurance Portability and
Accountability Act of 1996 (42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009 (42 U.S.C. &sect;17921 et seq.), the regulations promulgated pursuant to such laws, and all other comparable local,
state, federal, national, and foreign laws relating to the regulation of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
<U>Company Certificates</U>. Any certificate signed by an officer of the Company and delivered to the Underwriters or to counsel for
the Underwriters shall be deemed to be a representation and warranty by the Company to the Underwriters as to the matters set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
<U>Loans to Directors or Officers</U><I>.</I> There are no outstanding loans, advances (except normal advances for business expenses
in the ordinary course of business), or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of
the officers or directors of the Company, its Subsidiaries, or any of their respective family members, except as disclosed in the Registration
Statement, the General Disclosure Package, and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
<U>IT Systems</U>. Except as would not, individually or in the aggregate, have a Material Adverse Effect, the Company reasonably believes
that (i) the Company and the Subsidiaries own or have a valid right to access and use all computer systems, networks, hardware, software,
databases, websites, and equipment used to process, store, maintain, and operate data, information, and functions used in connection
with the business of the Company and the Subsidiaries (the &ldquo;<B><I>Company IT Systems</I></B>&rdquo;), (ii) the Company IT Systems
are adequate for, and operate and perform as required in connection with, the operation of the business of the Company and the Subsidiaries
as currently conducted, and (iii) the Company and the Subsidiaries have implemented reasonable backup, security and disaster recovery
technology consistent with applicable regulatory standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)
<U>ERISA</U>. Each &ldquo;employee benefit plan&rdquo; as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974,
as amended (&ldquo;<B><I>ERISA</I></B>&rdquo;) has been maintained in material compliance with its terms and the requirements of applicable
law. No employee benefit plan is subject to Title IV of ERISA. No &ldquo;prohibited transaction&rdquo; (as defined in either Section
406 of ERISA or Section 4975 of the Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;)) has occurred with
respect to any employee benefit plan that, individually or in the aggregate, could result in a Material Adverse Effect; and each employee
benefit plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and, to the Company&rsquo;s knowledge,
nothing has occurred, whether by action or by failure to act, which could cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, no officer or director of the Company or its subsidiaries or any beneficial
owner of five percent (5%) or more of shares of Common Stock or Common Stock Equivalents, has any direct or indirect affiliation or association
with any FINRA member (as determined in accordance with the rules and regulations of FINRA) that is participating in the Offering. Except
as set forth in the Registration Statement, the Preliminary Prospectus, the General Disclosure Package, and the Prospectus, to the Company&rsquo;s
knowledge, no proceeds from the sale of the Securities (excluding underwriting compensation as disclosed in the Registration Statement,
the General Disclosure Package, and the Prospectus) will be paid to any FINRA member, any persons associated with a FINRA member or an
affiliate of a FINRA member. Except as disclosed in the Registration Statement, the General Disclosure Package, and the Prospectus, the
Company has not issued any warrants or other securities or granted any options, directly or indirectly, to the Representative or any
of the Underwriters named on <U>Schedule I</U> hereto within the 180-day period prior to the initial filing date of the Prospectus. Except
as disclosed in Registration Statement, the General Disclosure Package, or the Prospectus and except for securities issued to the Representative
as disclosed in the Prospectus and securities sold by the Representative on behalf of the Company, no person to whom securities of the
Company have been privately issued within the 180-day period prior to the initial filing date of the Prospectus is a FINRA member, is
a person associated with a FINRA member or is an affiliate of a FINRA member. When used in this <U>Section 3.1(zz)</U> the term &ldquo;affiliate
of a FINRA member&rdquo; or &ldquo;affiliated with a FINRA member&rdquo; means an entity that controls, is controlled by or is under
common control with a FINRA member. The Company will advise the Representative and Underwriter Counsel if it learns that any officer,
director, or owner of five percent (5%) or more of the Company&rsquo;s outstanding shares of Common Stock or Common Stock Equivalents
is or becomes an affiliate or associated person of a FINRA member firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aaa)
<U>Contracts Affecting Capital</U>. There are no transactions, arrangements, or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity that involves
any structured finance, special purpose, or limited purpose entity that could reasonably be expected to materially affect the Company&rsquo;s
liquidity or the availability of or requirements for their capital resources required to be described or incorporated by reference in
the Registration Statement, the General Disclosure Package, and the Prospectus which have not been described or incorporated by reference
as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><U>Representations and Warranties of the Underwriters</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriters represent and warrant to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>No Testing-the-Waters Communications</U>. None of the Underwriters has (i) alone engaged in any Testing-the-Waters Communication and
(ii) authorized anyone to engage in Testing-the-Waters Communications. None of the Underwriters has distributed, or authorized anyone
else to distribute, any Written Testing-the-Waters Communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><U>Purchase and Sale</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Agreements to Sell and Purchase</U>. On the basis of the representations, warranties and covenants herein and subject to the conditions
herein and any adjustments made in accordance with Section 3(c) hereof,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company agrees to issue and sell the Closing Shares to the Underwriters; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Each Underwriter agrees to purchase from the Company, severally and not jointly, the number of Closing Shares set forth opposite its
name on Schedule I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The purchase price per Closing Share to be paid by the Underwriters to the Company shall be $3.72 (representing 93.0% of the price at
which the Closing Shares are initially offered to the public set forth on the cover page of the Final Prospectus). The Closing Shares
are to be offered initially to the public at the offering price set forth on the cover page of the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Payment for the Closing Shares (the &ldquo;<B><I>Closing Share Payment</I></B>&rdquo;) shall be made by wire transfer in immediately
available funds to the accounts specified by the Company to the Underwriters at the offices of Sichenzia Ross Ference Carmel LLP at 11:00
a.m., New York City time, on August 27, 2025 or at such other place on the same or such other date and time, not later than the fifth
Business Day thereafter, as the Underwriters and the Company may agree upon in writing (the &ldquo;<B><I>Closing Date</I></B>&rdquo;).
The Closing Share Payment shall be made against delivery of the Closing Shares to be purchased on the Closing Date to the Underwriters,
with any transfer taxes, stamp duties and other similar taxes payable in connection with the sale of the Closing Shares duly paid by
the Company. Delivery of the Closing Shares shall be made through the facilities of the Depository Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;),
unless the Underwriters shall otherwise instruct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Over-Allotment Option</U>. On the basis of the representations, warranties and covenants herein and subject to the conditions herein,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Underwriters are hereby granted an option (the &ldquo;<B><I>Over-Allotment Option</I></B>&rdquo;) to purchase, in the aggregate,
up to 562,500 additional shares of Common Stock, representing 15.0% of the Closing Shares sold in the offering from the Company (the
&ldquo;<B><I>Option Shares</I></B>&rdquo;). The purchase price to be paid per Option Share shall be equal to the price per Closing Share
set forth in Section 3(a) hereof. The Securities shall be issued directly by the Company and shall have the rights and privileges described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
upon an exercise of the Over-Allotment Option and subject to the terms and conditions herein, the Company agrees to issue and sell the
Option Shares to the Underwriters and each Underwriter agrees to purchase from the Company, severally and not jointly, the number of
shares specified in the Over-Allotment Exercise Notice (as defined in Section 3(b)(iii));</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Underwriters may exercise the Over-Allotment Option at any time in whole, or from time to time in part, on or before the forty-fifth
(45th) day following the Closing Date, by written notice from the Underwriters to the Company (the &ldquo;<B><I>Over-Allotment Exercise
Notice</I></B>&rdquo;). The Underwriters must give the Over-Allotment Exercise Notice to the Company at least two Business Days prior
to the Closing Date or the applicable Additional Closing Date, as the case may be. The Underwriters may cancel any exercise of the Over-Allotment
Option at any time prior to the Closing Date or the applicable Additional Closing Date, as the case may be, by giving written notice
of such cancellation to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Over-Allotment Exercise Notice shall set forth:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
the aggregate number of Option Shares as to which the Over-Allotment Option is being exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
the purchase price for the Option Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
the names and denominations in which the Option Shares are to be registered; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)
the applicable Additional Closing Date, which may be the same date and time as the Closing Date but shall not be earlier than the Closing
Date nor later than the tenth (10th) full Business Day after the date of the Over-Allotment Exercise Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Payment for the Option Shares (the &ldquo;<B><I>Option Shares Payment</I></B>&rdquo;) shall be made by wire transfer in immediately available
funds to the accounts specified by the Company to the Underwriters at the offices of Sichenzia Ross Ference Carmel LLP. at 11:00 a.m.
New York City time on the date specified in the corresponding Over-Allotment Exercise Notice, or at such other place on the same or such
other date and time, not later than the fifth Business Day thereafter, as the Underwriters and the Company may agree upon in writing
(an &ldquo;<B><I>Additional Closing Date</I></B>&rdquo;). The Option Shares Payment shall be made against delivery to the Underwriters
for the respective accounts of the Underwriters of the Option Shares to be purchased on any Additional Closing Date, with any transfer
taxes, stamp duties and other similar taxes payable in connection with the sale of the Option Shares duly paid by the Company. Delivery
of the Option Shares shall be made through the facilities of DTC unless the Underwriters shall otherwise instruct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Public Offering</U>. The Company understands that the Underwriters intend to make a public offering of the Closing Shares as soon
after the execution and delivery of this Agreement as in the judgment of the Underwriters is advisable, and initially to offer the Closing
Shares on the terms set forth in the Registration Statement and the Pricing Disclosure Package. The Company acknowledges and agrees that
the Underwriters may offer and sell Closing Shares to or through any Affiliate of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B><U>Covenants of the Company</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby covenants and agrees with each Underwriter as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Filings with the Commission</U>. The Company will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
prepare and file the Final Prospectus (in a form approved by the Underwriters and containing the Rule 430A Information) with the Commission
in accordance with and within the time periods specified by Rules 424(b) and 430A under the Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
file any Issuer Free Writing Prospectus with the Commission to the extent required by Rule 433 under the Securities Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
file with the Commission such reports as may be required by Rule 463 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Notice to the Underwriters</U>. The Company will advise the Underwriters promptly, and confirm such advice in writing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
when the Registration Statement has been declared effective by the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
when the Final Prospectus has been filed with the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
when any amendment to the Registration Statement has been filed or becomes effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
when any Rule 462(b) Registration Statement has been filed with the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
when any supplement to the Final Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication or any
amendment to the Final Prospectus has been filed or distributed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
of (x) any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Final Prospectus,
(y) the receipt of any comments from the Commission relating to the Registration Statement or (z) any other request by the Commission
for any additional information, including, but not limited to, any request for information concerning any Testing-the-Waters Communication;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
of (x) the issuance by the Commission of any order suspending the effectiveness of the Registration Statement or preventing or suspending
the use of the Registration Statement, the Pricing Disclosure Package, the Final Prospectus, any Preliminary Prospectus or any Issuer
Free Writing Prospectus or (y) the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or
pursuant to Section 8A of the Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
of the occurrence of any event or development within the Prospectus Delivery Period as a result of which, the Final Prospectus, the Pricing
Disclosure Package or, any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when
the Final Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any such Written Testing-the-Waters
Communication is delivered to a purchaser, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
of the issuance by any governmental or regulatory authority or any order preventing or suspending the use of any of the Registration
Statement, the Pricing Disclosure Package, the Final Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus or any
Testing-the-Waters Communication or the initiation or threatening for that purpose; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
of the receipt by the Company of any notice with respect to any suspension of the qualification of the Closing Shares for offer and sale
in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Ongoing Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
If during the Prospectus Delivery Period:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
any event or development shall occur or condition shall exist as a result of which the Final Prospectus as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances existing when the Final Prospectus is delivered to a purchaser, not misleading, the Company will, as
soon as reasonably possible, notify the Underwriters thereof and forthwith prepare and, subject to Section 4(e) hereof, file with the
Commission and furnish, at its own expense, to the Underwriters and to such dealers as the Underwriters may designate such amendments
or supplements to the Final Prospectus as may be necessary so that the statements in the Final Prospectus as so amended or supplemented
will not, in the light of the circumstances existing when the Final Prospectus is delivered to a purchaser, be misleading; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
it is necessary to amend or supplement the Final Prospectus to comply with applicable law, the Company will, as soon as reasonably possible,
notify the Underwriters thereof and forthwith prepare and, subject to Section 4(d) hereof, file with the Commission and furnish, at its
own expense, to the Underwriters and to such dealers as the Underwriters may designate such amendments or supplements to the Final Prospectus
as may be necessary so that the Final Prospectus will comply with applicable law; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
if at any time prior to the Closing Date or any Additional Closing Date, as the case may be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or
supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading,
the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to Section 4(e) hereof, file with the
Commission (to the extent required) and furnish, at its own expense, to the Underwriters and to such dealers as the Underwriters may
designate such amendments or supplements to the Pricing Disclosure Package as may be necessary so that the statements in the Pricing
Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package
is delivered to a purchaser, be misleading; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
it is necessary to amend or supplement the Pricing Disclosure Package to comply with applicable law, the Company will immediately notify
the Underwriters thereof and forthwith prepare and, subject to Section 4(d) hereof, file with the Commission (to the extent required)
and furnish, at its own expense, to the Underwriters and to such dealers as the Underwriters may designate such amendments or supplements
to the Pricing Disclosure Package as may be necessary so that the Pricing Disclosure Package will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Amendments, Supplements and Issuer Free Writing Prospectuses</U>. Before (i) using, authorizing, approving, referring to, distributing
or filing any Issuer Free Writing Prospectus, (ii) filing (x) any Rule 462(b) Registration Statement or (y) any amendment or supplement
to the Registration Statement or the Final Prospectus, or (iii) distributing any amendment or supplement to the Pricing Disclosure Package
or the Final Prospectus, the Company will furnish to the Underwriters and counsel for the Underwriters a copy of the proposed Issuer
Free Writing Prospectus, Rule 462(b) Registration Statement or other amendment or supplement for review and will not use, authorize,
refer to, distribute or file any such Issuer Free Writing Prospectus or Rule 462(b) Registration Statement, or file or distribute any
such proposed amendment or supplement (A) to which the Underwriters reasonably object in a timely manner and (B) which is not in compliance
with the Securities Act. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free
Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Delivery of Copies</U>. The Company will, upon request of the Underwriters , deliver, without charge, (i) to the Underwriters, three
signed copies of the Registration Statement as originally filed and each amendment thereto, in each case, including all exhibits and
consents filed therewith; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each
amendment thereto (without exhibits and consents) and (B) during the Prospectus Delivery Period, as many copies of the Final Prospectus
(including all amendments and supplements thereto and each Issuer Free Writing Prospectus) as the Underwriters may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Emerging Growth Company Status</U>. The Company will promptly notify the Underwriters if the Company ceases to be an Emerging Growth
Company at any time prior to the later of (i) completion of the distribution of the Closing Shares within the meaning of the Securities
Act and (ii) completion of the Lock-Up Period (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Blue Sky Compliance</U>. The Company will use its best commercially reasonable efforts, with the cooperation of the Underwriters,
if necessary, to qualify or register (or to obtain exemptions from qualifying or registering) the Securities and the Underwriters&rsquo;
Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Underwriters shall reasonably request
and will use its best commercially reasonable efforts, if necessary, to continue such qualifications, registrations and exemptions in
effect so long as required for the distribution of the Securities and the Underwriters&rsquo; Securities; <U>provided</U> that the Company
shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where
it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii)
subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Earning Statement</U>. The Company will timely file such reports pursuant to the Exchange Act as are necessary in order to make generally
available to its security holders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters
the benefits contemplated by, Rule 158(a) and Section 11(a) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Use of Proceeds</U>. The Company shall apply the net proceeds from the sale of the Closing Shares and the Option Shares in the manner
described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Clear Market</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
For a period of six (6) months from the effective date of the Registration Statement (the &ldquo;<B><I>Clear Market Period</I></B>&rdquo;),
the Company will not, without the prior written consent of the Underwriters (A) offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer
or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
shares of Common Stock, (B) or file or cause to be filed any registration statement under the Securities Act with the Commission relating
to the offering of any equity of the Company or any securities convertible into or exercisable or exchangeable for equity of the Company;
(C) enter into any agreement or announce the intention to effect any of the actions described in Sections 4(j)(i)(A) or 4(j)(i)(B) hereof,
or (D) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the
shares of Common Stock or any such other securities, whether any such transaction described in Sections 4(j)(i)(A) or 4(j)(i)(B) hereof
is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The restrictions contained in Section 4(j)(i) hereof shall not apply to: (A) the Securities, (B) the adoption of an equity incentive
plan and the grant of awards or equity pursuant to any equity incentive plan, and the filing of a registration statement on Form S-8
or any successor forms thereto relating to a Company Stock Plan described in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus; and (C) the issuance of equity securities in connection with an acquisition or a strategic relationship, which
may include the sale of equity securities. The recipient of any such shares of Common Stock or other securities issued or granted pursuant
to clauses (B) and (C) during the Clear Market Period shall enter into an agreement substantially in the form of Exhibit A hereto. In
no event should any equity transaction during Clear Market Period result in the sale of equity at an offering price to the public less
than the price at which the Closing Shares are offered to the public pursuant to the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Underwriters may, in their sole discretion, agree to release or waive the restrictions set forth in this Section 4(j) with respect
to the Company in which case the Underwriters will provide the Company with notice of the impending release or waiver substantially in
the form of Exhibit B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Notwithstanding the foregoing, this Section 4(j) shall not apply to Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>No Stabilization or Manipulation</U>. None of the Company, its Affiliates or any person acting on its or any of their behalf (other
than the Underwriters, as to which no covenant is given) will take, directly or indirectly, any action designed to or that constitutes
or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of any securities of the Company.
The Company acknowledges that the Underwriters may engage in passive market making transactions in the shares of Common Stock on the
Exchange in accordance with Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Investment Company Act</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from the sale of the
Securities in such a manner as would require the Company or any of its subsidiaries to register as an &ldquo;investment company&rdquo;
(as defined in the Investment Company Act) under the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Transfer Agent</U>. For the period of two years from the date of this Agreement, the Company shall engage and maintain, at its expense,
a registrar and transfer agent for the shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Reports</U>. For the period of two years from the date of this Agreement, the Company will furnish to the Underwriter, as soon as
they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities, and copies
of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation
system; <U>provided</U> that the Company will be deemed to have furnished such reports and financial statements to the Underwriters to
the extent they are filed on the Commission&rsquo;s Electronic Data Gathering, Analysis and Retrieval system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Right of First Refusal</U>. The Company agrees that it shall provide the Representative an irrevocable right of first refusal for
six (6) months from the effective date of the Registration Statement, to provide investment banking services to the Company on terms
that are the same or more favorable to the Company compared to terms offered to the Company by other underwriters or placement agents.
For these purposes, the investment banking services includes, without limitation, (a) acting as lead or joint-lead manager for any underwritten
public offering; (b) acting as lead or joint book-runner and/or lead or joint placement agent, or initial purchaser in connection with
any private offering of securities of the Company; and (c) acting as financial advisor in connection with any sale or other transfer
by the Company, directly or indirectly, of a majority or controlling portion of its capital stock or assets to another entity, any purchase
or other transfer by another entity, directly or indirectly, of a majority or controlling portion of the capital stock or assets of the
Company, and any merger or consolidation of the Company with another entity. The Representative shall notify the Company of its intention
to exercise the Right of First Refusal within 15 business days following notice in writing by the Company. Any decision by the Representative
to act in any such capacity shall be contained in separate agreements, which agreements would contain, among other matters, provisions
for customary fees for transactions of similar size and nature, as may be mutually agreed upon, and indemnification of the Representative
and shall be subject to general market conditions. In compliance with FINRA Rule 5110(g)(6)(A), in no circumstances shall the Right of
First Refusal have a duration of more than three (3) years from the earlier to occur of (i) commencement of sales of the public offering
and (ii) the termination date of the engagement between the Company and the Representative. If the Representative declines to exercise
the Right of First Refusal, the Company shall have the right to retain any other person or persons to provide such services on terms
and conditions which are not more favorable to such other person or persons than the terms declined by the Representative. The Right
of First Refusal granted hereunder may be terminated by the Company for &ldquo;Cause,&rdquo; which shall mean a material breach by the
Representative of the engagement letter or a material failure by the Representative to provide the services as contemplated by the engagement
letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
Any other opinions, certificates, or documents, as may reasonably be requested by the Underwriters or their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B><U>Covenants of the Underwriters</U></B>. Each Underwriter, severally and not jointly, hereby covenants and agrees with the Company
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Underwriter Free Writing Prospectus</U>. The Underwriters have not used, authorized the use of, referred to or participated in the
planning for use of, and will not use, authorize the use of, refer to or participate in the planning for use of, any Free Writing Prospectus
(which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into
the Registration Statement and any press release issued by the Company) other than (i) a Free Writing Prospectus that contains no &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule 433(d) under the Securities Act (&ldquo;<B><I>Issuer Information</I></B>&rdquo;)
that was not included in the Pricing Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus
listed in Schedule II hereto or prepared pursuant to Section 1(e)(iv) or Section 4(d) hereof (including any electronic road show), or
(iii) any Free Writing Prospectus prepared by the Underwriters and approved by the Company in advance in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Section 8A Proceedings</U>. None of the Underwriters is subject to any pending proceeding under Section 8A of the Securities Act with
respect to the offering of the Securities and will promptly notify the Company if any such proceeding against it is initiated during
the Prospectus Delivery Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B><U>Payment of Expenses</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Company Expenses</U>. The Company hereby agrees to pay on the Closing Date all expenses incident to the performance of the obligations
of the Company under this Agreement including, but not limited to: (a) all filing fees and expenses relating to the registration of the
Securities with the Commission; (b) all filing fees and expenses associated with the review of the offering of the Securities by FINRA;
(c) all fees and expenses relating to the listing of the Securities on the Exchange; (d) all fees, expenses and disbursements relating
to the registration or qualification of the Securities as the Underwriters may reasonably designate; (e) all fees, expenses and disbursements
relating to the registration, qualification or exemption of the Securities under the securities laws of such foreign jurisdictions as
the Underwriters may reasonably designate; (f) the costs of all mailing and printing of the underwriting documents, the Registration
Statement, Pricing Disclosure Package, the Final Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus or any Testing-the-Waters
Communication and all amendments, supplements and exhibits thereto as the Underwriters may reasonably deem necessary; (g) fees and expenses
of the transfer agent for the shares of Common Stock; (h) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities
from the Company to the Underwriters; (i) the fees and expenses of the Company&rsquo;s accountants; (k) the &ldquo;road show&rdquo; expenses;
(l) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (m) the fees and expenses of counsel
to the Underwriters. Subject to Section 11 hereof, the total amount payable to the Underwriters pursuant to Section 6(c) hereof shall
not exceed $150,000. The Underwriters may deduct from the net proceeds of the Offering payable to the Company on the Closing Date the
expenses set forth herein to be paid by the Company to the Underwriters. Except as provided for in this Agreement, the Underwriters shall
bear the costs and expenses incurred by them in connection with the sale of the Securities and the transactions contemplated thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Non-accountable Expenses</U>. On the Closing Date and on each Option Closing Date, the Company shall pay to the Underwriters, by deduction
from the net proceeds of the Offering a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received
by the Company from the sale of the Closing Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Underwriter Expenses</U>. Except to the extent otherwise provided in this Section 6 or Section 8 hereof, the Underwriters will pay
all of their own costs and expenses, including the fees and expenses of their counsel, any stock transfer taxes on resale of any of the
Securities held by them, and any advertising expenses connected with any offers they may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Accountable Expenses</U>. The Company agrees to reimburse the Representative no later than one (1) Business Day upon receipt of any
invoice for all of its reasonable, out-of-pocket expenses (including, but not limited to, travel, due diligence, reasonable fees and
expenses of its legal counsel, roadshow and background check on the Company&rsquo;s principals) for the performance of its services hereunder
not to exceed an aggregate of $150,000, of which includes the $35,000 advance previously paid and regardless of whether the Offering
occurs (the &ldquo;<B><I>Advance</I></B>&rdquo;). All documented out-of-pocket expenses of the Underwriters (including but not limited
to fees and disbursements of counsel to the Underwriters and reasonable and accountable travel) incurred in connection herewith which
shall be limited to expenses which are actually incurred as allowed under FINRA Rule 5110. If this Agreement is terminated pursuant to
<U>Section 10</U> hereof, or subsequent to a Material Adverse Change, the Company agrees to pay immediately any unreimbursed expenses
that have accrued as of such date less the Advance. To the extent that the Underwriters&rsquo; documented out-of-pocket expenses are
less than the Advance, the Underwriters will return to the Company that portion of the Advance not offset by actual expenses in accordance
with FINRA Rule 5110(g)(4)(A) and 5110(g)(4)(B).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Conditions of the Obligations of the Underwriters</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of the Underwriters to purchase the Closing Shares as provided herein on the Closing Date or the Option Shares as provided
herein on any Additional Closing Date, as the case may be, shall be subject to the timely performance by the Company of its covenants
and other obligations hereunder, and to each of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Compliance; No Stop Order</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Registration Statement and any post-effective amendment thereto shall have become effective, no stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto shall be in effect, and no proceeding for such purpose or pursuant
to Section 8A of the Securities Act shall be pending before or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company shall have filed the Final Prospectus and any Issuer Free Writing Prospectus with the Commission in accordance with and within
the time periods prescribed by Section 4(a) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company shall have (A) disclosed to the Underwriters all requests by the Commission for additional information relating to the offer
and sale of the Securities and (B) complied with such requests to the reasonable satisfaction of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct on
the date hereof and on and as of the Closing Date or any Additional Closing Date, as the case may be; and the statements of the Company
and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date
or any Additional Closing Date, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Accountants&rsquo; Comfort Letters</U>. On the date of this Agreement and on the Closing Date or any Additional Closing Date, as the
case may be, the Auditors shall have furnished to the Underwriters, at the request of the Company, letters, dated the respective dates
of delivery thereof and addressed to the Underwriter, in form and substance reasonably satisfactory to the Underwriters, containing statements
and information of the type customarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to
the financial statements and certain financial information contained in each of the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus; <U>provided</U> that the letter delivered on the Closing Date or any Additional Closing Date, as the case may
be, shall use a &ldquo;cut-off&rdquo; date no more than two Business Days prior to the Closing Date or such Additional Closing Date,
as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Material Adverse Change</U>. No event or condition of a type described in Section 1(l) hereof shall have occurred or shall exist,
which event or condition is not described in each of the Pricing Disclosure Package and the Final Prospectus (in each case, exclusive
of any amendment or supplement thereto), the effect of which in the reasonable judgment of the Underwriters makes it impracticable or
inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or any Additional Closing Date, as the
case may be, in the manner and on the terms contemplated by this Agreement, the Pricing Disclosure Package and the Final Prospectus (in
each case, exclusive of any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Opinion and Negative Assurance Letter of Counsel to the Company</U>. The Crone Law Group, P.C., counsel to the Company, shall have
furnished to the Underwriters, its (i) written opinion, addressed to the Underwriters and dated the Closing Date or any Additional Closing
Date, as the case may be, and (ii) negative assurance letter, addressed to the Underwriters and dated the Closing Date or any Additional
Closing Date, as the case may be, in a form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Officer&rsquo;s Certificate</U>. The Underwriters shall have received on and as of the Closing Date or any Additional Closing Date,
as the case may be, a certificate of an executive officer of the Company who has specific knowledge of the Company&rsquo;s financial
matters dated the Closing Date and any Additional Closing Date (if such date is other than the Closing Date) substantially in the form
attached hereto as &ldquo;<B><I>Exhibit D</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Secretary&rsquo;s Certificate</U>. The Underwriters shall have received on and as of the Closing Date or any Additional Closing Date,
as the case may be, a certificate of the Company signed by the Secretary of the Company, dated the Closing Date and any Additional Closing
Date (if such date is other than the Closing Date), certifying on behalf of the Company and not in an individual capacity substantially
to the effect that: (i) each of the articles of incorporation and the bylaws of the Company is true and complete, has not been modified
and is in full force and effect and (ii) the resolutions of the board of directors of the Company relating to the Offering are in full
force and effect and have not been modified; and as to (iii) the accuracy and completeness of all correspondence between the Company
or its counsel and the Commission; and (iv) the incumbency of the officers of the Company. The documents referred to in such certificate
shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Lock-Up Agreements</U>. The Lock-Up Agreements executed by the officers, directors and certain shareholders of the Company, each substantially
in the form of Exhibit A, shall have been delivered to the Underwriters on or before the date hereof, shall be in full force and effect
on the Closing Date or any Additional Closing Date, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Exchange Listing</U>. On the Closing Date or any Additional Closing Date, as the case may be, the Closing Shares and the Option Shares
shall have been approved for listing on the Exchange, subject to notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>No Legal Impediment to Issuance and Sale</U>. No action shall have been taken and no statute, rule, regulation or order shall have
been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date
or any Additional Closing Date, as the case may be, prevent the issuance, sale or delivery of the Securities by the Company; and no injunction
or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or any Additional Closing Date,
as the case may be, prevent the issuance, sale or delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Additional Documents</U>. On or prior to the Closing Date or any Additional Closing Date, as the case may be, the Underwriters and
counsel to the Underwriters shall have received such information, certificates and other additional documents from the Company as they
may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as contemplated herein or
in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the covenants, closing
conditions or other obligations, contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Chief Financial Officer&rsquo;s Certificate</U>. At the time this Agreement is executed, on the Closing Date and on each Option Closing
Date (should the letter delivered by the Auditor on such Option Closing Date pursuant to Section 7(c) not provide negative assurance
comfort to a cut-off date not more than three business days prior to such Option Closing Date), the Representative shall have received
a certificate of the chief financial officer of the Company dated such date certifying as to such matters and in form and substance as
the Representative may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
opinions, letters, certificates and other documents delivered pursuant to this Agreement will be deemed to be in compliance with the
provisions hereof only if they are reasonably satisfactory in form and substance to counsel to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this Section 7 is not satisfied when and as required to be satisfied, this Agreement and all obligations of
the Underwriters hereunder may be terminated by the Underwriters by notice to the Company at any time on or prior to the Closing Date
or any Additional Closing Date, as the case may be, which termination shall be without liability on the part of any party to any other
party, except that the Company shall continue to be liable for the payment of expenses under Section 6 and Section 11 hereof and except
that the provisions of Section 8 and Section 9 hereof shall at all times be effective and shall survive any such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B><U>Indemnification</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Indemnification of the Underwriters by the Company</U>. The Company agrees to indemnify and hold harmless each Underwriter, its Affiliates,
directors, officers, employees and agents and each person, if any, who controls the Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, damages and liabilities (including, without
limitation, all reasonable legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted,
as such fees and expenses are incurred), joint or several, that arise out of or are based upon (i) any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment or supplement thereto), or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary in order to make the statements therein not misleading,
or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Pricing Disclosure Package (including any
Pricing Disclosure Package that has subsequently been amended), the Final Prospectus (or any amendment or supplement thereto), any Preliminary
Prospectus, any Issuer Information, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication or any Road Show,
or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, in each case, except insofar as such losses, claims, damages or liabilities
arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with the Underwriter Information. The indemnity agreement set forth in this Section 8(a) shall be in addition to any liabilities
that the Company may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Indemnification of the Company by the Underwriters</U>. Each Underwriter agrees to indemnify and hold harmless the Company, its directors,
each officer who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, all reasonable legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim
asserted, as such fees and expenses are incurred), joint or several, to the same extent as the indemnity set forth in Section 8(a) hereof;
provided, however, that each Underwriter shall be liable only to the extent that any untrue statement or omission or alleged untrue statement
or omission was made in the Registration Statement (or any amendment or supplement thereto), any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), the Final Prospectus (or any amendment or supplement thereto), any
Preliminary Prospectus, any Issuer Information, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication or any
Road Show in reliance upon, and in conformity with, the Underwriter Information relating to the Underwriters. The indemnity agreement
set forth in this Section 8(d) shall be in addition to any liabilities that each Underwriter may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Notifications and Other Indemnification Procedures</U>. If any suit, action, proceeding (including any governmental or regulatory
investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant
to any of the preceding subsections of this Section 8, such person (the &ldquo;<B><I>Indemnified Person</I></B>&rdquo;) shall promptly
notify the person against whom such indemnification may be sought (the &ldquo;<B><I>Indemnifying Person</I></B>&rdquo;) in writing; <U>provided</U>
that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under any of the preceding
subsections of this Section 8 except to the extent that it has been materially prejudiced by such failure; and <U>provided</U>, further,
that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person
otherwise than under any of the preceding subsections of this Section 8. If any such proceeding shall be brought or asserted against
an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably
satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying
Person) to represent the Indemnified Person in such proceeding and shall pay the reasonable and documented fees and expenses of such
counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person
and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time
to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that
there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or
(iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified
Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between
them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in
the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all
Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for
(i) the Underwriters, its Affiliates, directors, officers, employees and agents and each person, if any, who controls the Underwriters
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall be designated in writing by the Underwriters;
and (ii) the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall be designated in writing by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Settlements</U>. The Indemnifying Person under this Section 8 shall not be liable for any settlement of any proceeding effected without
its written consent, which consent may not be unreasonably withheld, but if settled with such consent or if there be a final judgment
for the plaintiff, the Indemnifying Person agrees to indemnify the Indemnified Person from and against any loss, claim, damage, liability
or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall
have requested an Indemnifying Person to reimburse the Indemnified Person for any reasonably incurred and documented fees and expenses
of counsel as contemplated by this Section 8, the Indemnifying Person agrees that it shall be liable for any settlement of any proceeding
effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such Indemnifying Person
of the aforesaid request, (ii) such Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request,
or shall not have disputed in good faith the Indemnified Person&rsquo;s entitlement to such reimbursement, prior to the date of such
settlement and (iii) such Indemnified Person shall have given the Indemnifying Person at least 45 days&rsquo; prior notice of its intention
to settle. No Indemnifying Person shall, without the prior written consent of the Indemnified Person effect any settlement, compromise
or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any Indemnified Person
is or could have been a party and indemnity was or could have been sought hereunder by such Indemnified Person, unless such settlement,
compromise or consent (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory
to such Indemnified Person, from and against all liability on claims that are the subject matter of such action, suit or proceeding and
(y) does not include any statements as to or any findings of fault, culpability or failure to act by or on behalf of any Indemnified
Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B><U>Contribution</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent the indemnification provided for in Section 8 hereof is unavailable to or insufficient to hold harmless an Indemnified Person
in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each Indemnifying Person, in lieu of indemnifying
such Indemnified Person thereunder, shall contribute to the aggregate amount paid or payable by such Indemnified Person, as incurred,
as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect
the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities
pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions that resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this
Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant
to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discounts and commissions
received by the Underwriters, on the other hand, in each case as set forth in the table on the cover of the Final Prospectus bear to
the aggregate initial offering price of the Securities. The relative fault of the Company, on the one hand, and the Underwriters, on
the other hand, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the
Underwriters, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section 8 hereof, all reasonable legal or other fees or expenses incurred by such
party in connection with investigating or defending any action or claim. The provisions set forth in Section 8 hereof with respect to
notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 9; <U>provided</U>, however,
that no additional notice shall be required with respect to any action for which notice has been given under Section 8 hereof for purposes
of indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 9 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in
this Section 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of this Section 9, the Underwriters shall not be required to contribute any amount in excess of the amount by which the
total discounts and commissions received by the Underwriters in connection with the Securities distributed by it exceeds the amount of
any damages the Underwriters have otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11 of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 9, each director, officer, employee and agent of the Underwriters and each person, if any, who controls any
of the Underwriters within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same rights
to contribution as the Underwriters, and each director and officer of the Company who signed the Registration Statement, and each person,
if any, who controls the Company with the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, shall have the
same rights to contribution as the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remedies provided for in Section 8 and Section 9 hereof are not exclusive and shall not limit any rights or remedies which may otherwise
be available to any Indemnified Person at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B><U>Termination</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the delivery of and payment for the Securities on the Closing Date or any Additional Closing Date, as the case may be, this Agreement
may be terminated by the Underwriters in the absolute discretion of the Underwriters by notice given to the Company if after the execution
and delivery of this Agreement: (i) trading or quotation of any securities issued or guaranteed by the Company shall have been suspended
or materially limited on any securities exchange, quotation system or in the over-the-counter market; (ii) trading in securities generally
on any of Nasdaq shall have been suspended or materially limited; (iii) a general banking moratorium on commercial banking activities
shall have been declared by federal or New York state authorities; (iv) there shall have occurred a material disruption in commercial
banking or securities settlement, payment or clearance services in the United States; (v) there shall have occurred any outbreak or escalation
of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets,
or any substantial change or development involving a prospective substantial change in general economic, financial or political conditions
in the United States or internationally, or any change, amendment, interpretation, clarification or application of the listing standards,
policies, or guidance of Nasdaq that would adversely affect the eligibility of the Securities for listing, as in the reasonable judgment
of the Underwriters is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery
of the Securities on the Closing Date or any Additional Closing Date, as the case may be, in the manner and on the terms described in
the Pricing Disclosure Package or to enforce contracts for the sale of securities; or (vi) the Company or any of its subsidiaries shall
have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Underwriters
may interfere materially with the conduct of the business and operations of the Company and its subsidiaries, considered as one entity,
regardless of whether or not such loss shall have been insured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
termination pursuant to this Section 10 shall be without liability on the part of: (x) the Company to the Underwriters, except that the
Company shall continue to be liable for the payment of expenses under Section 6; (y) the Underwriters to the Company; or (z) any party
hereto to any other party except that the provisions of Section 8 and Section 9 hereof shall at all times be effective and shall survive
any such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B><U>Reimbursement of the Underwriters&rsquo; Expenses</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(a) the Company fails to deliver the Securities to the Underwriters for any reason at the Closing Date or any Additional Closing Date,
as the case may be, in accordance with this Agreement or (b) the Underwriters decline to purchase the Securities for any reason permitted
under this Agreement, then the Company agrees to reimburse the Underwriters for all reasonable out-of-pocket costs and expenses (including
the reasonable and documented fees and expenses of counsel to the Underwriters) incurred by the Underwriters in connection with this
Agreement and the applicable offering contemplated hereby, as provided by Section 6 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B><U>Representations and Indemnities to Survive Delivery</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
respective indemnities, rights of contribution, agreements, representations, warranties and other statements of the Company and the Underwriters
set forth in or made pursuant to this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement
or any certificate delivered pursuant hereto shall remain in full force and effect, regardless of any investigation made by or on behalf
of the Underwriters, the Company or any of their respective officers or directors or any controlling person, as the case may be, and
shall survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B><U>Notices</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, requests, consents, claims, demands, waivers and other communications under this Agreement shall be in writing and shall be
deemed to have been duly given (i) when delivered by hand (with written confirmation of receipt), (ii) when received by the addressee
if sent by a nationally recognized overnight courier (receipt requested), (iii) on the date sent by email of a PDF document (with confirmation
of receipt from the intended recipient by return email or other written acknowledgment) , or (iv) on the third day after the date mailed,
by certified or registered mail (in each case, return receipt requested, postage pre-paid). Such communications must be sent to the respective
parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this
Section 13):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Underwriter:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dominari
                                            Securities LLC</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">725
    5th Ave 23rd Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10022</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Eric Newman, Executive Vice President, Head of Investment Banking</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: enewman@dominarisecurities.com</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            a copy to</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(which
    shall not constitute notice):</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichenzia
    Ross Ference Carmel LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
    Avenue of the Americas, 31st Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10036</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Ross Carmel Esq. and Shane Wu Esq.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    rcarmel@ SRFC.LAW and swu@SRFC.LAW</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
    Pharmaceuticals Inc</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
                                            Jericho Plaza, Suite 101B,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
    NY 11753</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    diannejing@hotmail.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Jun Liu, Chief Executive Officer</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            a copy to</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(which
    shall not constitute notice):</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Crone Law Group, P.C.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">420
    Lexington Avenue, Suite 2446</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10710</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Joe Laxague</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    jlaxague@cronelawgroup.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this Section
13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B><U>Successors</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall inure solely to the benefit of and be binding upon the Underwriters, the Company and the other indemnified parties referred
to in Section 8 and Section 9 hereof, and in each case their respective successors. Nothing in this Agreement is intended, or shall be
construed, to give any other person or entity any legal or equitable right, benefit, remedy or claim under, or in respect of or by virtue
of, this Agreement or any provision contained herein. The term &ldquo;successors,&rdquo; as used herein, shall not include any purchaser
of the Securities from the Underwriters merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B><U>Equitable Remedies</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement acknowledges and agrees that (a) a breach or threatened breach by the Company of any of its obligations under
Section 4(j) or Section 4(o) would give rise to irreparable harm to the Underwriters for which monetary damages would not be an adequate
remedy and (b) if a breach or a threatened breach by the Company of any such obligations occurs, the Underwriters will, in addition to
any and all other rights and remedies that may be available to such party at law, at equity, or otherwise in respect of such breach,
be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance of the terms of Sections
4(j) or 4(o), as applicable, and any other relief that may be available from a court of competent jurisdiction, without any requirement
to (i) post a bond or other security, or (ii) prove actual damages or that monetary damages will not afford an adequate remedy. Each
party to this Agreement agrees that such party shall not oppose or otherwise challenge the existence of irreparable harm, the appropriateness
of equitable relief or the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent
with the terms of this Section 15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B><U>Severability</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<B><U>Governing Law</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance
with the law of the State of New York applicable to agreements made and to be performed in such state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<B><U>Consent to Jurisdiction</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
legal suit, action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby (each, a &ldquo;<B><I>Related
Proceeding</I></B>&rdquo;) may be commenced, prosecuted or continued in any court other than the courts of the State of New York located
in the City and County of New York or in the United States District Court for the Southern District of New York, which courts (collectively,
the &ldquo;<B><I>Specified Courts</I></B>&rdquo;) shall have jurisdiction over the adjudication of any Related Proceeding, and the parties
to this Agreement hereby irrevocably consent to the exclusive jurisdiction the Specified Courts and personal service of process with
respect thereto. The parties to this Agreement hereby irrevocably waive any objection to the laying of venue of any Related Proceeding
in the Specified Courts and irrevocably waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought
in any Specified Court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<B><U>Waiver of Jury Trial</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties to this Agreement hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by
jury in any Related Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<B><U>No Fiduciary Relationship</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that: (i) the purchase and sale of the Securities pursuant to this Agreement, including the determination
of the offering price of the Securities and any related discounts and commissions, is an arm&rsquo;s-length commercial transaction between
the Company, on the one hand, and the Underwriters, on the other hand; (ii) in connection with each transaction contemplated hereby and
the process leading to such transaction each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary
of the Company or its Affiliates, stockholders, members, partners, creditors or employees or any other party; (iii) no Underwriter has
assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to any of the transactions contemplated
hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other
matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement; (iv) the Underwriters and
their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company,
and the Underwriters have no obligation to disclose any of such interests by virtue of any fiduciary or advisory relationship; and (v)
the Underwrites have not provided any legal, accounting, regulatory or tax advice in any jurisdiction with respect to the offering contemplated
hereby, and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent they deemed appropriate. The
Company waives and releases, to the full extent permitted by applicable law, any claims it may have against the Underwriters arising
from an alleged breach of fiduciary duty in connection with the offering of the Securities or any matters leading up to the offering
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<B><U>Compliance with the USA Patriot Act</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct
Terrorism (USA Patriot Act) Act of 2001, Title III of Pub. L. 107-56, the Underwriters are required to obtain, verify and record information
that identifies its clients, including the Company, which information may include the name and address of its clients, as well as other
information that will allow the Underwriters to properly identify its respective clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<B><U>Entire Agreement</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this
Agreement) that relate to the offering of the Securities, represents the entire agreement among the Company and the Underwriters with
respect to the preparation of the Registration Statement, the Pricing Disclosure Package, the Final Prospectus, each Preliminary Prospectus,
each Issuer Free Writing Prospectus, each Testing-the-Waters Communication, the purchase and sale of the Securities and the conduct of
the offering contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
<B><U>Amendments or Waivers</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be
effective unless the same shall be in writing and signed by all the parties hereto. No waiver by any party shall operate or be construed
as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different
character, and whether occurring before or after the waiver. No failure to exercise, or delay in exercising, any right, remedy, power
or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise
of any right, remedy, power or privilege hereunder preclude any other or further exercise of any other right, remedy, power or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
<B><U>Section Headings</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.
<B><U>Counterparts</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one
and the same agreement. Counterparts may be delivered via email (including PDF or any electronic signature complying with the U.S. federal
ESIGN Act of 2000) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly delivered
and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.
<B><U>Recognition of the U.S. Special Resolution Regimes</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event that an Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective
to the same extent as the transfer would be effective under the U.S. Special Resolution Regime (as defined below) if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event that an Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined below) of such Underwriter becomes subject
to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised
against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As used in this section:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;BHC
Act Affiliate&rdquo;</I></B> has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance
with, 12 U.S.C. &sect; 1841(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Covered
Entity&rdquo;</I></B> means any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Default
Right&rdquo;</I></B> has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;U.S.
Special Resolution Regime&rdquo;</I></B> means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.
<B><U>Definitions</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, the following terms shall have the meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Additional
Closing Date&rdquo; </I></B>has the meaning set forth in Section 3(b)(v) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Affiliate&rdquo;
</I></B>has the meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Applicable
Time&rdquo;</I></B> means 5:00 p.m., New York City time on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Business
Day&rdquo;</I></B> means a day other than a Saturday, Sunday or any other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay-at-home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Commission&rdquo;
</I></B>means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Emerging
Growth Company</I></B><I>&rdquo;</I> means an &ldquo;emerging growth company&rdquo; as defined in Section 2(a)(19) of the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Exchange
Act&rdquo;</I></B> means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Exempt
Issuance</I></B>&rdquo; means securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which
is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the
Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Final
Prospectus&rdquo;</I></B> means the prospectus in the form first filed with the Commission pursuant to and within the time limits described
in Rule 424(b) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Free
Writing Prospectus&rdquo;</I></B> has the meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;GAAP&rdquo;
</I></B>means generally accepted accounting principles as applied in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Investment
Company Act&rdquo;</I></B> means the Investment Company Act of 1940, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Issuer
Free Writing Prospectus&rdquo;</I></B> means an &ldquo;issuer free writing prospectus&rdquo; as defined in Rule 433(h)(1) under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Person</I></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Preliminary
Prospectus&rdquo;</I></B> means any preliminary prospectus included in the Registration Statement prior to the time at which the Commission
declared the Registration Statement effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Pricing
Disclosure Package&rdquo;</I></B> means, collectively the Pricing Prospectus, any Issuer Free Writing Prospectus and with the documents
and pricing information set forth in Schedule II hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Pricing
Prospectus&rdquo;</I></B> means the Preliminary Prospectus included in the Registration Statement at the time at which the Commission
declared the Registration Statement effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Prospectus
Delivery Period&rdquo;</I></B> means such period of time after the first date of the public offering of the Closing Shares as in the
opinion of counsel for the Underwriters a prospectus relating to the Closing Shares is required by law to be delivered (or required to
be delivered but for Rule 172 under the Securities Act) in connection with sales of the Closing Shares by the Underwriters or any dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Registration
Statement&rdquo;</I></B> means (a) the registration statement on Form S-1 (File No. 333-275062), including a prospectus, registering
the offer and sale of the Closing Shares and any Option Shares under the Securities Act at the time the Commission declared it effective,
including each of the exhibits, financial statements and schedules thereto, (b) any Rule 430A Information, and (c) any Rule 462(b) Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Road
Show&rdquo; </I></B>means a &ldquo;road show&rdquo; (as defined in Rule 433(h)(4)) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Rule
430A Information&rdquo;</I></B> means the information deemed to be part of the Registration Statement pursuant to Rule 430A under the
Securities Act at the time the Commission declared the Registration Statement effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Rule
462(b) Registration Statement&rdquo;</I></B> means a registration statement to register the offer and sale of additional Closing Shares
pursuant to Rule 462(b) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Sarbanes-Oxley
Act&rdquo;</I></B> means the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Securities
Act&rdquo;</I></B> means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Testing-the-Waters
Communication&rdquo;</I></B> means any oral communication or Written Communication with potential investors undertaken in reliance on
Section 5(d) of the Securities Act and Rule 163B thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Written
Communication&rdquo;</I></B> has the meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Written
Testing-the-Waters Communications&rdquo;</I></B> means any Testing-the-Waters Communication that is a Written Communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>[SIGNATURE
PAGE FOLLOWS]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURANEX
    PHARMACEUTICALS INC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jun Liu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jun
    Liu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
and agreed as of the date first above written:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dominari Securities LLC </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric Newman</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Newman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President, Head of Investment Banking</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SCHEDULE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Closing Shares to Be</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchased</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Dominari Securities LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">2,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Revere Securities LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Pacific Century Securities, LLC.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Total:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SCHEDULE
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
Disclosure Package</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Closing Shares:</FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">3,750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Option Shares:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">562,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Offering Price per Closing Share:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Discount per Closing Share:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Discount per Option Share:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SCHEDULE
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SCHEDULE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock
Up Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
    Period</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jun Liu</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dian Ying Jing</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Helen Hsu</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Huijuan Zhong</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Yong Yan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Haiyan Yang</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Xiaohui Hao</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Ning Zhang</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liqin Xie</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chang Liu</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Lock-Up Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOMINARI
SECURITIES LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">725
5th Ave 23rd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that Dominari Securities LLC (the &ldquo;<B>Underwriter</B>&rdquo;), propose to enter into an underwriting agreement
(the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with Curanex Pharmaceuticals Inc, a company incorporated under the law of the State
of Nevada (the &ldquo;Company&rdquo;), providing for the initial public offering (the <B>&ldquo;Public Offering&rdquo;</B>) of 3,750,000
shares of common stock (the &ldquo;<B>Common Stock</B>&rdquo;), par value $0.0001 per share, of the Company (each, a &ldquo;<B>Closing
Share</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce the Underwriters to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of the Underwriter, the undersigned will not, during the period commencing on the date hereof and ending six (6)
months after the effective date of the Registration Statement relating to the Public Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;),
(1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common
Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock, whether now owned or hereafter acquired
by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;<B>Lock-Up
Securities</B>&rdquo;); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled
by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration
of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any
transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent
of the Underwriters in connection with</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
    relating to Lock-Up Securities acquired in open market transactions after the completion of the Public Offering; provided that no
    filing under Section 13 or Section 16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;),
    or other public announcement shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities
    acquired in such open market transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
    of Lock-Up Securities as a <I>bona fide </I>gift, by will or intestacy or to a family member or trust for the benefit of the undersigned
    (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship by blood, marriage or adoption, not more
    remote than first cousin);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
    of Lock-Up Securities to a charity or educational institution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up Securities
    to another corporation, partnership or other business entity that controls, is controlled by or is under common control with the
    undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates (as defined
    in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a trust, to a trustee or beneficiary of the trust; provided that in the case of any transfer pursuant to the foregoing
    clauses (b), (c) (d) or (e), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and
    deliver to the Underwriters a lock-up agreement substantially in the form of this agreement and (iii) no filing under Section 13
    or Section 16(a) of the Exchange Act or other public announcement shall be required or shall be voluntarily made during the Lock-Up
    Period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the undersigned from the Company of shares of Common Stock upon the vesting of restricted stock awards or stock units
    or upon the exercise of options to purchase the Company&rsquo;s shares of Common Stock issued under an equity incentive plan of the
    Company or an employment arrangement described in the Pricing Prospectus (as defined in the Underwriting Agreement) (the &ldquo;Plan
    Shares&rdquo;) or the transfer or withholding of shares of Common Stock or any securities convertible into shares of Common Stock
    to the Company upon a vesting event of the Company&rsquo;s securities or upon the exercise of options to purchase the Company&rsquo;s
    securities, in each case on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis or to cover tax obligations of the undersigned
    in connection with such vesting or exercise, provided that if the undersigned is required to file a report under Section 13 or Section
    16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Lock-Up Period, the
    undersigned shall include a statement in such schedule or report to the effect that the purpose of such transfer was to cover tax
    withholding obligations of the undersigned in connection with such vesting or exercise and, provided further, that the Plan Shares
    shall be subject to the terms of this agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transfer of Lock-Up Securities pursuant to agreements described in the Pricing Prospectus under which the Company has the option
    to repurchase such securities or a right of first refusal with respect to the transfer of such securities, provided that if the undersigned
    is required to file a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership
    of shares of Common Stock during the Lock-Up Period, the undersigned shall include a statement in such schedule or report describing
    the purpose of the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, provided that
    (i) such plan does not provide for the transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement
    or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding
    the establishment of such plan, such public announcement or filing shall include a statement to the effect that no transfer of Lock-Up
    Securities may be made under such plan during the Lock-Up Period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transfer of Lock-Up Securities that occurs by operation of law, such as pursuant to a qualified domestic order or in connection with
    a divorce settlement, provided that the transferee agrees to sign and deliver an agreement substantially in the form of this agreement
    for the balance of the Lock-Up Period, and provided further, that any filing under Section 13 or Section 16(a) of the Exchange Act
    that is required to be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer has
    occurred by operation of law; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transfer of Lock-Up Securities pursuant to a <I>bona fide</I> third party tender offer, merger, consolidation or other similar transaction
    made to all holders of shares of Common Stock involving a change of control (as defined below) of the Company after the closing of
    the Public Offering and approved by the Company&rsquo;s board of directors; provided that in the event that the tender offer, merger,
    consolidation or other such transaction is not completed, the Lock-Up Securities owned by the undersigned shall remain subject to
    the restrictions contained in this agreement. &ldquo;Change of control&rdquo; means the consummation of any <I>bona fide</I> third
    party tender offer, merger, amalgamation, consolidation or other similar transaction the result of which is that any &ldquo;person&rdquo;
    or &ldquo;group&rdquo; of persons (as defined in Section 13(d)(3) of the Exchange Act) becomes the beneficial owner (as defined in
    Rules 13d-3 and 13d- 5 of the Exchange Act) of a majority of total voting power of the voting stock of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally
applicable to any issuer-directed or &ldquo;friends and family&rdquo; securities that the undersigned may purchase in the Public Offering;
(ii) the Underwriters agree that, at least three (3) Business Days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Underwriters will notify the Company of the impending release or
waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through
a major news service at least two (2) Business Days before the effective date of the release or waiver. Any release or waiver granted
by the Underwriters hereunder to any such officer or director shall only be effective two (2) Business Days after the publication date
of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer
of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this
lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the Company and the Underwriters are relying upon this lock-up agreement in proceeding toward consummation
of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&rsquo;s
heirs, legal representatives, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that, if the Underwriting Agreement is not executed by August 29, 2025 or if the Underwriting Agreement (other
than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the shares
of Common Stock to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has duly executed and delivered this Lock-Up Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position
    in the Company, if any:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notices:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXH<FONT STYLE="text-transform: uppercase">IBIT
B</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Clear Market Release and Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*],
202[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
Pharmaceuticals Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
Jericho Plaza, Suite 101B,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
NY 11753</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Clear Market Release and Waiver</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 4(j)(iii) of the underwriting agreement, dated August 25, 2025 (the <B><I>&ldquo;Underwriting Agreement&rdquo;</I></B>), between
Curanex Pharmaceuticals Inc, a company incorporated under the law of the State of Nevada (the <B><I>&ldquo;Company&rdquo;</I></B>), and
Dominari Securities LLC (the <B><I>&ldquo;Underwriter&rdquo;</I></B>), the Underwriter hereby agree to release and waive the restrictions
in Section 4(j) of the Underwriting Agreement to allow the Company to sell up to [*] shares of its common stock [solely from and including
[*] to and including [*]].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOMINARI SECURITIES LLC</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Lock-Up Waiver Press Release</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURANEX
PHARMACEUTICALS INC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*]<B>,
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
Pharmaceuticals Inc (the &ldquo;Company&rdquo;) announced today that Dominari Securities LLC, acting as the Underwriter in the Company&rsquo;s
recent public offering of the Company&rsquo;s shares of Common Stock, is [waiving] [releasing] a lock-up restriction with respect to
the Company&rsquo;s shares of Common Stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver]
[release] will take effect on [*], and the shares may be sold on or after such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is
prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act of 1933, as amended.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Officer&rsquo;s Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*],
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 7(f) of the Underwriting Agreement dated August 25, 2025 (the &ldquo;Underwriting Agreement&rdquo;), by and between Curanex
Pharmaceuticals Inc, a company incorporated under the law of the State of Nevada (the &ldquo;<U>Company</U>&rdquo;), and Dominari Securities,
LLC as the underwriter, the undersigned, Jun Liu, Chief Executive Officer of the Company, hereby certifies in such capacity the following
on behalf of the Company as of the date of this certificate as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus, and the Final Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
In my opinion, the Registration Statement, as amended, as of the date it was declared effective by the Commission and as of date hereof
did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
In my opinion, the Pricing Disclosure Package as of the Applicable Time and as of the date hereof, any Issuer Free Writing Prospectus
as of its date and as of the date hereof, and the Final Prospectus as of the date thereof and as of date hereof did not include any untrue
statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances in which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
To my knowledge after reasonable investigation as of the date hereof, the representations and warranties of the Company in the Underwriting
Agreement are true and correct, and the Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied under the Underwriting Agreement at or prior to the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
There has not been, subsequent to the date of the most recent audited financial statements included in the Pricing Disclosure Package,
a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used herein without definition shall have the respective meanings ascribed to them in the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jun
    Liu</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 180px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Curanex
Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
New York, August 26, 2025 &mdash; Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (&ldquo;Curanex&rdquo; or the &ldquo;Company&rdquo;), a
developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced
the pricing of its initial public offering (the &ldquo;Offering&rdquo;) of 3,750,000 shares of common stock at a public offering price
of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering is
being conducted on a firm commitment basis. The Company&rsquo;s shares of common stock are expected to begin trading on the Nasdaq Capital
Market on August 26, 2025, under the ticker symbol &ldquo;CURX.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering,
to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses. The
Offering is expected to close on August 27, 2025, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the proceeds from the Offering for: (i) the development of our lead product candidate, Phyto-N, for the treatment
of ulcerative colitis; (ii) to conduct FDA-required good laboratory practice (&ldquo;GLP&rdquo;) toxicology and pharmacokinetic studies
for Phyto-N in ulcerative colitis, (iii) to prepare and submit an Investigational New Drug (IND) application, and (iv) for working capital
and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dominari
Securities LLC is acting as the lead underwriter for the Offering, with Pacific Century Securities LLC and Revere Securities LLC acting
as co-underwriters. The Crone Law Group, P.C. is acting as counsel to the Company. Sichenzia Ross Ference Carmel LLP is acting as lead
counsel to the underwriters with respect to the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
registration statement on Form S-1, as amended (File No. 333-282686) relating to the Offering was previously filed with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) and subsequently declared effective by the SEC on August 12, 2025. The Offering is being
made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be
filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
copies of the final prospectus related to the Offering may be obtained, when available, from Dominari Securities LLC, 725 5th Avenue,
23rd Floor, New York, NY 10022, or by telephone at (212) 393-4500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete
information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer
to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an
offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Curanex Pharmaceuticals Inc</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curanex
Pharmaceuticals Inc is a developmental stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and
developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven
anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands
of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has validated Phyto-N&rsquo;s effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19,
diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will
advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit the Company&rsquo;s website at <B><U>www.curanexpharma.com</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Forward-Looking
Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>All
statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to,
the Company&rsquo;s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based
on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition,
results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed.
Investors can identify these forward-looking statements by words or phrases such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;aim,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo;
&ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;is/are likely to&rdquo; or other similar expressions. The Company undertakes
no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations,
except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results
may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results
in the Company&rsquo;s registration statement and in its other filings with the SEC.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Curanex
Pharmaceuticals Inc</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Attn:
Liqin Xie, Chief Operating Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>info@curanexpharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $4 5T# 2(  A$! Q$!_\0
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M5]!A\33Q*O!GU6%QE+%QYJ;VW1+11174=H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?.7[4'[1W_  @<
M$OA;PW.#XAF3_2;I.?L:$=!_TT(_(<^E85JT*$'.>QS8C$0PU-U*CT-'X_\
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MIQW14?B5S]854*H & .!2TR&43PQR+]UU##\13Z_1#]9"BBB@ HHHH ****
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M]IKXK>,O#'QCUC3M)\3:GIUC'' 4M[>X9$7,:DX'N:\M_P"%[?$3_H=-:_\
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MH%?IK_PPO\%/^A-B_P# F;_XJOI,5B,-A9*$Z>_9(\+#T<1B(N49[>;/S/\
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M;1T7ZK]3T\CQ%U+#RZ:K]3OIO]4_^Z:_!?Q%_P C!JG_ %]R_P#H9K]Z)O\
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M_B:^DQ6%P^+DISG:WFCPL/B*V'BXQAOY,_5+_AM+X*_]#]I__?$G_P 371>
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>curx-20250825.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6NKbP9z5Z8CekhvWB6bfkqXy0jxR4RxSzgpZ4G0eMM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CURX="http://curanexpharmaceuticalsinc.com/20250825" elementFormDefault="qualified" targetNamespace="http://curanexpharmaceuticalsinc.com/20250825">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://curanexpharmaceuticalsinc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="curx-20250825_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="curx-20250825_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>curx-20250825_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>curx-20250825_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="curx-20250825.xsd#Cover" roleURI="http://curanexpharmaceuticalsinc.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://curanexpharmaceuticalsinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 25,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-282686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Curanex
Pharmaceuticals Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002025942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0741390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2
                                            Jericho Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
                                            101B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jericho<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">673-6078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CURX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://curanexpharmaceuticalsinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>curx-20250825.xsd</File>
    <File>curx-20250825_lab.xml</File>
    <File>curx-20250825_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "CURX",
   "nsuri": "http://curanexpharmaceuticalsinc.com/20250825",
   "dts": {
    "schema": {
     "local": [
      "curx-20250825.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "curx-20250825_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "curx-20250825_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://curanexpharmaceuticalsinc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://curanexpharmaceuticalsinc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-25-012316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-012316-xbrl.zip
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M[1E=D'>^JP6:5J*FEK\!4$L#!!0    ( ,H[&EO10$AQ_0H  '^&   5
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M#_TVD^;P7]<$@4"'L=9)22E%6NOCA83#E+7N7P2LO2T"UCV+@'6(BX#UT$7
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MH"(8U:(]G9^EARR )/Z\OR</1*CW#I9DEWV6.WKJ.,,8$.OZ[&UP<\R3N=[
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M@(2_HF;'$8*Q"58LK'""SX)_5DW$"ZM&^G<G/58@[NM%!+L^2Q+TFN&WZ'B
M5X#&N<YZEL!+\,&A[I3(P#_+"BW!*GB?%U>PR><)SKU,X!DY6].^X-Z5UOI4
MQ_N>ZBQ56D/B';%76J?H_=0@'C'Z0>:XA<$\G=,)!3>FCL#)9!L%Q-]7 8&C
M =AO"AUMXF@*52PDY^9+(3O-K1>M08/5);BSE5%N\,T(EAALH12.Y )]+C@D
MQ3*E T*?ZWR@3/YL4O&*9O(P5J'D-,'WP4$#O8('&3ZRC-XG-&KSUBK0S^(
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M,GX1:9X&/-#AW+>#@T/3&H*KTT*.\SI\:W>@;::X;DZA*PMN8.2V*.L'Z.[
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M6V<G/U;\Y+5(CV?!:_:,$DK@FS51I@^C<$0GOVES_8[!L$/6OY7ZU. .K\E
M![8=EVM+SOYA\ HAR)L.%2V)#2NU3ID;#0')ODR++'(=P,X^A,Y^,(2H3!9-
MY=S89MUMF@_O2S* N$B">Y2P'U;9N?I#<^/.=QYM#L4Y9NETSR\.UUE6$Q;3
MX%=XHR7B#U -31239(5L0<&D&BX4!ZFE]!;! W/.^8*11_$;RGG2SQ2IHA\7
MZ&G3D="=#^W[3$P-PQ851B$\6)5M@--U>+>K[2WO2;H^D^D<X_E,!(_;J$D[
M^I#"LUOUOHU!T6?1&6D??0_"[&/1-HT9<_L)/S\&YZ'LJ"5="<KOU^>$\UY)
MKYPL37!Y\KA9SDI4&"&&YTK\4YQ%Z9)V1<.O=";A@!;:ETB1!(>0PV=FNA5L
MNK&Z?8VQZRZ0;5XDC QF#XF8M?#C%.H>ZJG5#_3Y0FSZS;"&KP^PA@.LX0!K
M."A@5, K VOXMS5GR^!9LHB:3("1KY)4LK)6*><;HOZIY.W;-C+57.%IS=B
M;8=79^L'!-YSW!$W(@LVX;R(V>*39'.*39AHI*;A'[4C)%>@B"7_A1DB(1^
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M"+!!F\J^RH,WHN;]"Z)J?7C)']8[@4[:74L8^6AP"EBO8%$>S!"Y-[&^.JC
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MW:CC>@'*#MGT(]=3T<#P D\2K)E<T3!#$[2PE[S;OLF2B1F25NM'< =8K#D
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MKCL%!ZFF6L[*Z^*)Z^#L U=J)O0E6A++_#64A=@>DNLDO<:C5M;+.'>ZEL,
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M+8O'-JJUM>A24H_% 1R!CSLX9XYE>*2@[,WBT[GSK <(9OBS,$P9,W. T6B
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M2LLB9[:'"G;#8,S_Z_CH*#PZ.N)R30(-\VU%O:J2N4HOF,QY-ZVVA<_)IS'
M&F5WX.V:UCX)-H3D[*PJB96+8QX0?!5N,;C;HMV[\'RL61Y5[KLBS7CMCDP'
MFT3:,>^'4W+B_1C;0L!JA5:D,J; 10^ Z"81C5/>N5PER#>.P%BGT]@V-U+<
MHK^NO<<.CA;F"2=O1?Z%F4'?F)F!1*C(NLM_L$%N:5JW.863:CPB4(AV]%$D
M3L"93DE[=G=3TIV:_20^22[HSNB@.KTL0JG,YIJ6DCL(:!,@;52&$L_=R?#
MR3UNCC=1\G4(_CN$:DX3)J-?^@T+!IV0S\T]$D/%N8=(^Z._$S \16')#^=F
M1?Q'U$6,DK>O=8\ JPTNGV=8:2WH:[Q0&]@>6/4HJZF'8A4MDEJX4!*[VB'=
M[#"@IF3L$Q-]AM*^3FI L#X\GW/#JZHN2F)"A><W&(1H2OH]!6XQAB K4".<
MG:]7]!@(HK[]^F=XPO#]OT%7'A+CGY?VFOSQ![L:2A/_FA@@WSD!_D_ QDD
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M5Q-I6Q>/Q8K(?A*GZ8LE[+$M4-Q"V.$S0.=FRR%(I8Y>G[+S<0CH-%0*K1;
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MV,%>(Q[6ORYGTB<Q>2?]U4W3.[>%QZ/KWGF;1?":5O&F9/)& SGX>_;Q\"1
M@W\.IO)]O9OWQH;>(.;7M*9[M$L/2\U=&LY#V@6OJ4_E:K>TBR$2_QOJ9<-7
MMUC9=Q;F_[Q.\1;<P^,#[N& >]A3W,/G==#V/\,TF7-&[<0H;/BL8PSB'; 9
M,I!(W>Y3;J0Q2:<!<FB>AXJ/^(M_( X*^F>9+)*2<S]%:*LKR#[$EAW$7;)3
M"0BZXOIY!?OO4%8D*-T-2'YS30T_H1]^@8]&#*<WK5UJ!C99JH-OZY@@<L</
M7N?(]%DEF2&K]3\ ?UX97 IL%V;&Y]LPS^&.*\ZU"4.KL"!HS64*@LOT(6SU
M(U[&"A(&)$EX?,&A&(NAG-@17KE]T*%YK%<#Q/@8!@_H$@W-:G(R]5L)>.OM
M1%P+MOB(L@7C21GZWGDNX BP:>49:-46-3.A:NI;VMYV(=_=6OHP<"'CYOT)
M0R/F#9&F<A"#J7G/BP(,QPB>C\<6.6)01H3]E,BBG)4>CWJ6FJPV&?9@%5_0
MPR*SE>WCD.[?DVE-$KYCW%;(IR1%_8P/(=,G:Z%1'W%IJ*X[DPL731V YUXB
M+ XOH+[NT(0(PB@53#V9.V*\0<U'J"K2<]2[<")9?$TK-*=F##TS5$D@QO0G
M#.8ZQ50!1_PNTEG*5^IX%!=YQ85?]%!Z L[D"1_XE"?1H6-#A1(1UT51+GD6
MO4#"'>?@U4/R)(*)+J@[X$#'.S4*:2?X1LC.'%6ZN>O=3:A,_-5R'$CN>^?$
MIV2@9B,V*_OIH,_JZ%^1M0-GS&>F.1:L.9XO$QS6>?!S65S!W:#: J6\&>*-
M47Z8P4AOZD$&85?@U"JY>90'K9=:%L7!O \SRF.U'!Q?NJ 3%P!I3<)!4*13
MRK-,(@4O^G??> 27GU43W?>\+.+W#WY;:>&/VR!Q!E?[U?1P<^[)M";G+/]/
MLP8DX/VZ#7CL"CWBRU%GS_#FI.KB,F8^;\?:2Q88>:Q":XK%!5A\I0?7]2Y/
MRG>::!R%"QGCNQ9,//71"29\%HH968K)AV2YXG8\5-XLWQ!@O'X)?IRVK3ME
M"G?'\,^RPHX(XY'SN2Z&V+$6*_LY^)A9PBRZHFN(+'@7:=P?W.1T7?>JX)CJ
M#=:\LY!(OICFC41./>AT%<HR\=9('U:[K&D^'G%I+09(LP(OS\K2I*F7UZ=X
M=EMMYV-/ A!$\N'GR1RESP9D10*IA6MF&N:88:!1 8I*!8:2GA@K@).$?3]6
MA0J>.HE8/2%5%?A9CCVC<>5L:9I;;\_#BU^A>4 I $Z$XFAL%X;6N"HCQS:8
MP&[D>9)CWUHU?.C#24FT8K""Y"]5&T:A<0#T%,6WJ\'Q7M!5$7W@"0]^&V0D
M-5Z3'7Q5:&[@H,'W9%J3"[%@(J9&,';Y@/X6YY_$T&-!=!UW/'///X##DY\G
M 1D#W-5L0X)>Q#E#"A1M%D3MH+$Y$)^J=7!19'-)\B@J;%5&<2T)%.Q4S=.H
M'"R!*AFII$#=&FKJ2-1%?RL:_,T,AK7 ,: 2!+6&%A32.TI0Z?CQ=]B5'9^F
MF;#C8_Q-;XG[X5#LR;2H @ .Q6]<#/>:ZW)Z['B^3S"'Q^9[GM1:Q>-0IK@-
M@-H]5.1J\]O[J(5-$39"1L1P/8+@6>,ACO@;TK.I-5+ISK2YW\FV"CXS.'*&
MQR/KLAX$>4^F-?F#!?DT \48_!*5[Y/Z4(FT-\!$TD,OT,P4?G+R"](/P>2;
M:;"$3U\X6L:2C+KM&@>";MVV?ZZ(B&?>[O76AU@CY)-&Y#@M@P$';4*NUFE?
MC!1CA>0<A<&*:B1#:HH4TEV+USK;M/@;:I9$Q9XK+D-FQ*+YE *C0MLQUWXZ
M:'V8'WE>1GGM?"KD[#I^^"HJ2[%D[(/5^"=#U_:)X]0+,]XL,.=3PB9DY!N
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M"/4C-#9>DYLM"2$<61*KI*XSYDUWF\8-#W1@D)C^BZH+[[!^[-+I3XV>^N:
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MD:;X'73&+*&:MI@9ZR4<1V@3SXYH+^3264@+@$\M\;(+)O%6]R'?-;T]ZPU
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MD(M]<M/TK':N6[ JL=ZT]]7$ST+]$LB:Y'8*<>)"I8U56)0#@!\Q"8@$RUS
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MJ:?:XM(8VLE/[M(P!3B'P3ZM2X..C/@TP=]Q:0K)ZBX-:;O$!:UYX!D%GCW
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M?K'WLB'=%--$$NOU\0BK;5R$HX!55IH,+@,H#929R48N:[2X]NCC3DG'\L*
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MUC CURK@\N58Y"'?)X7+V.BU1"*Y4/65Q(.[QO5-_:=2$+NA2#B_$P4<59^
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MYTV1?I6K Y(JF\1^481N+9B3QA:=]7E7.K;B"%2I%\Z+G_&JC*1=PV>T;ZI
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M"_SW;MC5X8&?]O=/%UC"EO/#0Q1+K 0W@-L:JI^T6962H;/)'ZL IV> )3#
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MC(T)122')O,))\TDX#A0BR3Y=G"S2!7./&A,:\9S=L<B]9E[G2B,@8OGH5;
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MZEJ*'<C<C]*+$"G//CF"L8AA:BP1?^6J*[D@$3'JB95O,2S]."S'^/=3DL"
M0'AM+Q8@VTTU$-_["D'S8N%U:/$PM9##:^\1X'ZA$^BI)$]4+(6#4#*VE=)U
MRR?@;?+]_9PR]=5Z0@O8\F2KS#_B3>(M)_RJJJ%SR4F]-M"?$?"_:&!F=Z+5
M2+SSU /X"KJ@09^V:GV^6C^<49C_:^,9\/^J=71X"D?B1'DB!M*Z;2?IZ4[2
M-]7K^=]R9.#;N]Y'_W>#].>%_P502P,$%     @ RCL:6Z%GCUX*%P  PZ\
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MJA&0*HB$@C#(_YC)'$UL1J_3'0:V%("Q!!W#YZ@E$2:"$F+_="HK,GA8K%]
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M.KI$I,\M@,<=,F8D0O!+]VYZKCL8()Y@X7LLY [ G<3RR2M=6!%?",N)&P1
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M   1              "  0    !C=7)X+3(P,C4P.#(U+GAS9%!+ 0(4 Q0
M   ( ,H[&EO10$AQ_0H  '^&   5              "  68#  !C=7)X+3(P
M,C4P.#(U7VQA8BYX;6Q02P$"% ,4    " #*.QI;L_ X0&H'  #V5P  %0
M            @ &6#@  8W5R>"TR,#(U,#@R-5]P<F4N>&UL4$L! A0#%
M  @ RCL:6S_N":C#M0  H&H%  D              ( !,Q8  &5X,2TQ+FAT
M;5!+ 0(4 Q0    ( ,H[&EOR6H_$C P  &4X   *              "  1W,
M  !E>#DY+3$N:'1M4$L! A0#%     @ RCL:6Z%GCUX*%P  PZ\   L
M         ( !T=@  &9O<FTX+6LN:'1M4$L%!@     &  8 ;0$   3P
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="curx-20250825.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002025942</identifier>
        </entity>
        <period>
            <startDate>2025-08-25</startDate>
            <endDate>2025-08-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-25" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-25" id="Fact000004">0002025942</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-25" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-25" id="Fact000010">2025-08-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-25" id="Fact000011">Curanex Pharmaceuticals Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-25" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-25" id="Fact000013">333-282686</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-25" id="Fact000014">83-0741390</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-25" id="Fact000015">2                                             Jericho Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-25" id="Fact000016">Suite                                             101B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-25" id="Fact000017">Jericho</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-25" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-25" id="Fact000019">11753</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-25" id="Fact000020">(718)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-25" id="Fact000021">673-6078</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-25" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-25" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-25" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-25" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-25" id="Fact000026">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-25" id="Fact000027">CURX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-25" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-25" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-08-25" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
